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(57) ABSTRACT 
The subject technology relates to arylquinoline compounds 
and their use for treating cancer or cancer metastasis. The 
compounds of the subject technology promote cells to 
secrete a pro-apoptotic tumor suppressor, i.e., prostate apop­
tosis response-4 (Par-4), which in tum promote apoptosis in 
cancer cells or metastatic cells. 
13 Claims, 5 Drawing Sheets 
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Legend of reagents: a, arylacetonitrile, terl-BuOK, DMF, 90°C, 3-4h; b, 2(2'­
fluorophenyl)acetyl chloride, Et3N, reflux 2h and then K2C03, DMF, 90
°C, 4h; c, 2,4-bis(4-
methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane (Lawesson's reagent), dioxane, 
reflux 5h; d, (+)-biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine, K2C03, DMF, 12h; e, 
POCl3, reflux, 3h; f, Zn, CH3C02H, 75°C, 1 h.
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ARYLQUINOLINE AND ANALOG 
COMPOUNDS AND USE THEREOF TO 
TREAT CANCER 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a U.S. National Phase under 35 U.S.C. 
§371 oflnternational Application No. PCT/US2014/066796,
filed Nov. 21, 2014, which claims the benefit of U.S.
Provisional Application No. 61/907,817, filed Nov. 22,
2013, the entire disclosures of which are hereby incorpo­
rated by reference herein.
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This work was supported by National Center for Research 
Resources in a grant entitled "COBRE Center for Biomedi-
2 
ment of cancer or for the treatment or inhibition of cancer 
metastasis in a subject in need thereof comprising adminis­
tering to the subject an effective amount of the compound or 
a pharmaceutically acceptable salt thereof or a composition 
5 thereof. 
Other advantages of the subject technology include com­
pounds for use in promoting the secretion of Prostate 
Apoptosis Response-4 (PAR-4) from cells or for use in 
promoting apoptosis of a cancer cell in a subject comprising 
10 
administering to the subject an effective amount of an 
arylquinoline or analog compound or a pharmaceutically 
acceptable salt thereof or a composition thereof. 
15 
In one aspect of the subject technology, the arylquinoline 
is a compound according to Formula (I): 
(I) 
cal Research Excellence" grant P20 RR020171; and NIH/ 20 
NCI ROI CA60872 (to VMR). The government has certain 
rights in the subject technology. 
TECHNICAL FIELD 
The present invention relates to compounds that treat 
cancer and/or treat or prevent cancer metastasis. In particu­
lar, the subject technology is directed to arylquinoline com­
pounds and analogs thereof such as arylquinolone or aryl­
thioquinolone compounds, described as "arylquin" 
compounds, that promote cells to secrete a pro-apoptotic 
tumor suppressor, such as prostate apoptosis response-4 
(Par-4), which promotes apoptosis in cancer cells or meta­
static cells. 
BACKGROUND 
Lung cancer is the most frequently diagnosed cancer and 
the leading cause of cancer-related deaths in the world. The 
most common alterations in lung cancer include activating 
mutations in ras genes and inactivating mutations in the p53 
gene. Lung tumor cells with p53 mutations or deletions often 
develop resistance to chemotherapy and radiation therapy, 
leading ultimately to the death of the patients. Notably, such 
p53-deficient cancer cells are susceptible to apoptosis by the 
proapoptotic tumor suppressor, Par-4. 
Par-4 is a tumor suppressor protein that induces apoptosis 
in diverse cancer cells but not in normal cells. Par-4 is 
ubiquitously expressed in normal cells and tissues, but is 
sequestered by an intermediary filament protein, vimentin, 
and hence, circulating levels of Par-4 are generally low. If it 
were secreted by normal cells at appreciably higher levels 
than normal, certain cancer cells would be susceptible to its 
effects. Extracellular Par-4 binds a receptor GRP78, which 
appears only on the cancer cell surface, and induces apop­
tosis by caspase-dependent mechanisms. In contrast, normal 
cells express low to undetectable levels of basal or inducible 
cell-surface GRP78 and are resistant to apoptosis by extra­
cellular Par-4. 
or a pharmaceutically acceptable salt thereof; wherein n is 1, 
25 2, 3, 4, 5, or 6, for each NR1 R2, R1 and R2 are independently 
H, alkyl, alkoxy, aryl, heteroaryl; Ar is aryl or heteroaryl, 
which can be further substituted with halogen, amino, alky­
lamino, dialkylamino, arylalkylamino, N-oxides of dialky­
lamino, trialkylammonium, mercapto, alkylthio, alkanoyl, 
30 nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, 
sulfonyl, sulfonamide, CONR3R4, NR3CO(R4), NR3COO 
(R4), NR3CONR4R5 where R3, R4, R5, are independently, H, 
alkyl, aryl, heteroaryl or a fluorine; X represents halogen; m 
is 1, 2, 3, 4, or 5. 
35 In one aspect of the present disclosure, n is 1 to 3; m is 
1 to 3 and X is selected from fluorine or chlorine, e.g. X is 
one, two or three fluorine substituents, or X is one, two or 
three chlorine substituents, or X represents at least one 
fluorine and at least one chlorine on Ar. In various embodi-
40 ments, the compound of Formula (I) includes wherein n is 
at least 2 or 2 and one NR1 R2 group is at the 2 position of 
the quinoline ring and another NR1 R2 group is at the 7 
position of the quinoline ring; and Ar-Xm is at the 3 position 
of the quinoline ring. In other embodiments, Ar is phenyl, m 
45 is 2 and X is selected from fluoro or chloro. In further 
embodiments, m is 1 and the Ar-Xm group at the 3 position 
of the quinoline ring is an ortho fluoro or ortho chloro phenyl 
group. In still other embodiments, the Ar-Xm group at the 3 
position is a halogen substituted heteroaryl, e.g., pyridyl, 
50 pyrolidyl, piperidyl, or pyrimidyl having one or more halo­
gen substituents. For each of the embodiments, each of R1 
and R2 of each NR1R2 can be independently H, or a lower 
alkyl. 
In another aspect, the subject technology relates to com-
55 pounds where the Ar-Xm group is located at the 3 position 
of the quinoline, quinolone or thioquinolone ring and Ar is 
a phenyl group such as shown in formulas (II) or (III): 
Therefore, there is a need for compounds that are Par-4 60 
secretagogues and promote the secretion of Par-4 which in 
turn promotes apoptosis in cancer cells and metastatic cells. 
I 
-
1
-Xm 
(II) 
SUMMARY OF THE DISCLOSURE 
Advantages of the subject technology include arylquino­
line and analog compounds and compositions for the treat-
65 
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3 
-continued
(III) 
4 
In another aspect, the subject technology relates to a kit 
which includes the compounds of the subject technology. In 
an embodiment related to this aspect, the kit includes one or 
more compounds of Formula (I), (II) and/or (II). In another 
5 embodiment, the kit includes one or more other therapeutic 
compounds for use in combination therapies. 
Additional advantages of the subject technology will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
or a pharmaceutically acceptable salt thereof. In Formulas 
(II) and (III), Z is O or S; and n, Ri, R2, X and m are as
defined for the compound of Formula (I). The compounds of
Formula (III) are arylquinolones and arylthioquinolones
when Z is O or S, respectively, and are useful in the same
manner as the compounds according to Formula (I). For ease
of reference, the compounds of Formulas (I), (II), (III) will
10 embodiment of the disclosure is shown and described, 
simply by way of illustration of the best mode contemplated 
of carrying out the disclosure. As will be realized, the 
disclosure is capable of other and different embodiments, 
and its several details are capable of modifications in various 
15 obvious respects, all without departing from the disclosure. 
be referred to herein as arylquinoline or arylquin com­
pounds.
In various embodiments, the compounds of Formula (II) 
20 
and Formula (III) have n as 1, 2, or 3 and m as 1, 2, or 3, 
e.g., the compounds include one NR1 R2 group at the 2
position of the quinoline ring and another NR1 R2 group at 
the 7 position of the quinoline ring, and X is selected from 25 
fluoro or chloro. In other embodiments, the compounds of 
Formula (II) or (III) have n as 2, m as 2 and X selected from 
fluoro or chloro. In still further embodiments, the com­
pounds of Formula (II) or (III) have n as 2, m as 1 and X 
selected as chloro or fluoro at the ortho position of the 30 
phenyl ring. For each of the embodiments, each R1 and R2 
of each NR1 R2 can be independently H, or a lower alkyl. 
Another aspect of the subject technology includes a 
biotinylated derivative or other detectably labeled alterna­
tive of each of Formulas (I), (II) and (III) and their various 35 
embodiments. 
Accordingly, the drawings and description are to be regarded 
as illustrative in nature, and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying drawings, which are included to pro­
vide further understanding of the subject technology and are 
incorporated in and constitute a part of this specification, 
illustrate aspects of the subject technology and together with 
the description serve to explain the principles of the subject 
technology. 
FIG. 1 is an exemplary illustration showing methods for 
synthesis of arylquinolines, arylquinolones, and arylthioqui­
nolones. 
FIG. 2 shows charts illustrating the induced apoptosis in 
cancer cells by an arylquinoline of the present disclosure. 
Normal cells (MEFs, HELs, HBEC, PrE, prostate stromal 
cells PrS) or lung cancer cells (human A549 and H460, 
mouse LLCl and KP7B) and prostate cancer cells (PC-3 
MM2, DU145, LNCaP) were treated with the indicated 
amounts (0.5, 1 and 10 µM) of Arylquin 1 or vehicle (V) for 
24 h, and apoptosis was determined by ICC for active 
caspase-3. Data shown represent mean values from three 
independent experiments±s.d. Asterisks (**) or(*) indicate 
In another aspect, the subject technology relates to phar­
maceutical compositions of arylquinoline compounds, e.g., 
one or more compounds of Formula (I), Formula (II) and/or 
Formula (III), and/or one or more pharmaceutically accept­
able salts thereof, in combination with a pharmaceutical 
additive, e.g., a pharmaceutically acceptable carrier and/or 
excipient. In an embodiment related to this aspect, the 
subject technology relates to a pharmaceutical composition 
including an effective amount of at least one arylquinoline 
compound. 
40 statistical significance (P<0.0001) or (P<0.001 ), respec­
tively, by the Student t test. 
FIG. 3 shows apoptosis activity for an arylquinoline of the 
present disclosure. Top: Cancer cells were co-cultured with 
MEFs and treated with Arylquin 1 (500 nM) or vehicle and 
In another aspect, the subject technology relates to a 
method of treating cancer and/or treating or inhibiting 
cancer metastasis in a subject, e.g., a human. In an embodi­
ment relating to this aspect, a therapeutically effective 
amount of one or more arylquinoline compounds, pharma­
ceutical salts and/or compositions thereof is administered to 
45 tested for apoptosis. Bottom: Serum from mice injected with 
Arylquin 1 (Aq) or corn oil vehicle (V), was examined by 
Western blot analysis (not shown). Aliquots of serum from 
these mice were either directly added to the growth medium 
of cells in culture, or incubated with the indicated antibody, 
50 and then added to the growth medium of PC-3 MM2 cells to 
test for apoptosis. 
a subject in need thereof to treat cancer and/or treat or inhibit 
cancer metastasis in the subject. 
FIGS. 4A and 48 are bar graphs illustrating percent cell 
surface GRP-78 expression and apoposis activity for an 
arylquinoline of the present disclosure. FIG. 4A is a bar 
55 graph showing cell surface GRP78 levels in cancer cells 
treated with CM from MEFs exposed to Arylquin 1. Par-
4+/+ MEFs or Par-4-/- MEFs were treated with vehicle or 
Arylquin 1 (500 nM) for 24 h. The CM from these MEFs 
was incubated with the indicated cancer cells for 24 h. The 
In another aspect, the subject technology relates to a 
method for promoting secretion of Prostate Apoptosis 
Response-4 (Par-4) from cells or promoting apoptosis of 
cancer cells in a subject in need thereof by administering to 
the subject an effective amount of one or more arylquinoline 
compounds or compositions in accordance with the subject 60 
technology. 
In another aspect, the subject technology relates to a 
method for screening for compounds that inhibit vimentin 
binding to PAR-4, comprising exposing a solution including 
vimentin and PAR-4 to a test compound and detecting the 65 
level of vimentin-PAR-4 complex formation by Western blot 
analysis, for example. 
cancer cells were then subjected to FACS analysis for cell 
surface GRP78 expression. Data shown represent mean 
values of three experiments±s.d. Asterisks (**) or (*) indi­
cate statistical significance (P<0.0001) or (P<0.001), respec­
tively, based on two-way ANOVA with data normality and 
equality of variance assumptions. FIG. 48 is a bar graph 
showing the apoptotic activity of secreted Par-4 is inhibited 
by the presence of a neutralizing antibody against cell 
US 9,873,670 B2 
5 
surface GRP78. Par-4+/+ MEFs or Par-4-/- MEFs were 
treated with vehicle or Arylquin 1 (Aq, 500 nM) for 24 h. 
The CM from these cells was then treated with GRP78 
antibody (GRP78 Ab) or control IgG antibody (Control Ab) 
and incubated with the indicated cancer cells. After 24 h, the 
cancer cells were scored for apoptosis by ICC for active 
caspase-3. Apoptosis data shown represent mean values of 
three experiments±s.d. Asterisks (**) or (*) indicate statis­
tical significance (P<0.0001) or (P<0.001 ), respectively, 
based on two-way ANOVA. 
10 
FIG. 5 is a bar graph showing apoptosis activity in PC-3 
cells. The CM from Vim-/- MEFs was treated with the 
indicated antibody (Ab) and tested for apoptosis of cancer 
cells. The CM from Vim+/+ or Vim-/- cells served as 
15 
additional controls. Data shown represent mean values from 
three independent experiments±s.d. Asterisks (**) indicate 
statistical significance (P<0.0001) by the Student t test. 
6 
secretion of Par-4 in vitro and in vivo by selectively target­
ing an intermediate filament protein, vimentin. 
The arylquinoline compounds of the present disclosure 
include compounds according to Formula (I): 
(I) 
wherein n is 1, 2, 3, 4, 5, or 6, for each NR1R2, R1 and R2 
are independently H, alkyl, alkoxy, aryl, heteroaryl; Ar is 
aryl, e.g., phenyl, naphthyl, and heteroaryl, e.g., pyridyl, 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
20 
pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl, which can 
be further substituted with halogen, amino, alkylamino, 
dialkylamino, arylalkylamino, N-oxides of dialkylamino, 
trialkylammonium, mercapto, alkylthio, alkanoyl, nitro, In general, the subject technology relates to Par-4 secre­
tagogues that induce the release of Par-4 from normal cells 
thereby triggering the paracrine apoptosis of cancer cells. In 
accordance with the subject technology, certain arylquino­
line compounds have been identified as Par-4 secretagogues 
which induce or promote Par-4 secretion at low (nanomolar) 
concentrations from both normal lung fibroblasts and epi­
thelial cells. The arylquinoline compounds and their phar- 30 
maceutically acceptable salts and compositions are useful 
for the treatment of colorectal cancer, prostate cancer, brain 
cancer, liver cancer, breast cancer and lung cancer. In 
particular, the arylquinoline compounds and their pharma­
ceutically acceptable salts and compositions are particularly 35 
useful in the treatment of lung cancer and prostate cancer. 
25 
nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfo­
nyl, sulfonamide, CONR3R4, NR3CO(R4), NR3COO(R4), 
The Par-4 gene was first identified in 1994 in prostate 
cancer cells undergoing apoptosis. This gene encodes a 
pro-apoptotic protein, Prostate Apoptosis Response-4 or 
Par-4, which is remarkably effective in inducing cancer cell 40 
apoptosis and tumor regression in animal models. Par-4 does 
not affect normal cells. Par-4 protein is secreted in cell 
culture-conditioned medium (CM) or systemically in mice 
by normal cells, and extracellular Par-4 binds to its receptor 
GRP78 on the cancer cell surface and induces apoptosis. 45 
Normal cells express low to undetectable levels of cell 
surface GRP78 and are resistant to apoptosis by extracellular 
Par-4. 
NR3CONR4R5 where R3, R4, R5, are independently, H, 
alkyl, aryl, heteroaryl or a fluorine; X represents halogen, 
e.g., a fluorine, chlorine, bromine, or iodine substituent; m is
1, 2, 3, 4, 5. This embodiment also includes pharmaceuti­
cally acceptable salts of Formula (I). 
In one aspect of the present disclosure, n is 1 to 3; m is 
1 to 3 and X is selected from fluorine or chlorine, e.g. X is 
one, two or three fluorine substituents, or X is one, two or 
three chlorine substituents, or X represents at least one 
fluorine and at least one chlorine on Ar. In various embodi­
ments, the compound of Formula (I) includes wherein n is 
at least 2 or 2 and one NR1 R2 group is at the 2 position of 
the quinoline ring and another NR1R2 group is at the 7 
position of the quinoline ring; and Ar-Xm is at the 3 position 
of the quinoline ring. In other embodiments, Ar is phenyl, m 
is 2 and X is selected from fluoro or chloro. In further 
embodiments, m is 1 and the Ar-Xm group at the 3 position 
of the quinoline ring is an ortho fluoro or ortho chloro phenyl 
group. In still other embodiments, the Ar-Xm group at the 3 
position is a halogen substituted heteroaryl, e.g., pyridyl, 
pyrolidyl, piperidyl, or pyrimidyl having one or more halo-
50 gen substituents. For each of the embodiments, each of R1 
and R2 of each NR1 R2 can be independently H, or a lower 
alkyl. 
Par-4 induces apoptosis in many types of cancer cells. For 
cancer cells that may be resistant to direct apoptosis by 
Par-4, overexpression of Par-4 in these cells renders them 
supersensitive to a broad range of apoptotic insults, includ­
ing chemotherapeutic agents, TNF, or ionizing radiation. 
Applicants have also found that GRP78 levels can be 
increased on the surface of diverse cancer cells to overcome 55 
Par-4-resistance by inhibition of NF-KB activity, which is 
usually elevated in most cancer cells. Therefore, the arylqui­
noline compounds of the subject technology can be admin­
istered either alone or in combination with a second active 
ingredient such as a chemotherapeutic agent or an NF-KB 60 
inhibitor for treating cancer or cancer metastasis. 
As the baseline levels of Par-4 secreted by normal cells 
are generally inadequate to cause massive apoptosis in 
cancer cell cultures, secretogogues that bolster the release of 
Par-4 would constitute an important therapeutic advance. 65 
The subject technology thus relates to a new class of 
"small-molecule" secretagogues, that promote the desired 
In another aspect, the subject technology relates to com­
pounds where the Ar-Xm group is located at the 3 position 
of the quinoline ring and Ar is a phenyl group such as shown 
in formulas (II) or (III): 
I 
-
1
-Xm 
(II) 
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(III) 
or a pharmaceutically acceptable salt thereof; wherein Z is 
O or S; and n, R
1
, R
2
, X and m are as defined for the 
compound of Formula (I). 
8 
In the following detailed description, numerous specific 
details are set forth to provide a full understanding of the 
subject technology. It will be apparent, however, to one 
ordinarily skilled in the art that the subject technology may 
be practiced without some of these specific details. In other 
instances, well-known structures and techniques have not 
been shown in detail so as not to obscure the subject 
technology. 
To facilitate an understanding of the present subject 
10 technology, a number of terms and phrases are defined 
below: 
The term "unit dose" or "dosage" refers to physically 
In one aspect of this embodiment, the compounds of 
Formula (II) and Formula (III) have n as 1, 2, or 3 and m as 15
1, 2, or 3, e.g., the compounds include one NR
1
R
2 
group at 
the 2 position of the quinoline ring and another NR
1 
R
2 
group 
discrete units suitable for use in a subject, each unit con­
taining a predetermined-quantity of the therapeutic compo­
sition calculated to produce the desired responses discussed 
above in association with its administration, i.e., the appro-
priate route and treatment regimen. The quantity to be 
administered, both according to number of treatments and 
unit dose, depends on the protection or effect desired. 
at the 7 position of the quinoline ring, and X is selected from 
fluoro or chloro. In other embodiments, the compounds of 
20 
Formula (II) or (III) have n as 2, m as 2 and X selected from 
The term "treat" and "treatment" refer to both therapeutic 
treatment and prophylactic, inhibition or preventative mea­
sures, wherein the object is to inhibit, prevent or slow down 
(lessen) an undesired pathological change or disorder, such 
as the development or spread of cancer. For purpose of this 
disclosure, beneficial or desired clinical results include, but 
are not limited to, alleviation of symptoms, diminishment of 
fluoro or chloro. In still further embodiments, the com­
pounds of Formula (II) or (III) have n as 2, m as 1 and X 
selected as chloro or fluoro at the ortho position of the 
phenyl ring. For each of the embodiments, each R
1 
and R
2 25
of each NR
1 
R
2 
can be independently H, or a lower alkyl. 
Another aspect of the subject technology includes a 
biotinylated derivative or other detectably labeled alterna­
tive of each of Formulas (I), (II) and (III) and their various 
embodiments. 
Particular arylquinoline compounds of the subject tech­
nology include 3-(2-fluorophenyl)-N7,N7 -dimethylquino­
line-2, 7-diamine ( Ary lquin 1 ); 3-(3-fluoropheny l)-N7 ,N7 -
dimethylquinoline-2,7-diamine (Arylquin 2); 3-(4-
fluoropheny l)-N7 ,N7 -dimethy lquinoline-2, 7 -diamine 
( Ary lquin 3); 7 -( dimethylamino )-3-(2-fluoropheny l)quino­
lin-2(1 H)-one (Arylquin 4); 7-(dimethylamino )-3-(2-fluoro­
phenyl)quinoline-2(1H)-thione (Arylquin 5); 3-(2-fluoro­
phenyl)-N,N-dimethylquinolin-7-amine (Arylquin 6); 3-(2-
fluorophenyl)quinolin-2-amine (Arylquin 8); N-(2-(2-(2-(2-
(7-( dimethylamino )-3-(2-fluorophenyl)quinolin-2-ylthio) 
acetamido )ethoxy )ethoxy)ethyl)-5-(2-oxohexahydro-l H-
thieno[3,4-d]imidazol-4-yl)pentanamide (Biotinylated 
Arylquin 9). 
One of these novel secretagogues, namely Arylquin-1 
(FIG. 1), causes particularly robust secretion of Par-4 pro­
tein from normal cells and elevates systemic levels of Par-4, 
thereby providing an effective strategy for the induction of 
apoptosis of circulating cancer cells as well as the inhibition 
of the growth of primary and metastatic tumors. 
For example, lung cancer, the leading cause of cancer 
deaths in the US, is commonly associated with oncogenic 
K-Ras and loss of tumor suppressor p53 function contrib­
uting to therapy resistance. Lung cancer cells that express
oncogenic Ras or are deficient in p53 function are, however, 
sensitive to apoptosis by the tumor suppressor protein Par-4. 
Applicants have found that elevated levels of Par-4 secreted 
from the normal cells in response to Arylquin-1 are adequate 
to induce paracrine apoptosis of p53-wild type and p53-
deficient lung cancer cells as well as those expressing 
oncogenic K-ras. These findings imply that secretagogues
like Arylquin-1 functionally trigger the secretion of Par-4 
from normal cells to induce apoptosis of lung cancer cells.
Applicants have further found that endogenous vimentin
binds to and sequesters Par-4, and that the Arylquin-1
secretagogue functions by binding to vimentin and releasing
Par-4 for secretion.
extent of disease, stabilized (i.e., not worsening) state of 
disease, delay or slowing of disease progression, ameliora­
tion or palliation of the disease state, and remission (whether 
30 partial or total), whether detectable or undetectable. For 
example, "treatment" can include a qualitative or quantita­
tive reduction (e.g., by at least 10%, 20%, 30%, 40%, 50%, 
60%, 70%, 80%, 90%, 95%, or more) in the tumor or 
metastases size or reduce, inhibit, or prevent metastatic 
35 growth. "Treatment" can also mean prolonging survival as 
compared to expected survival if not receiving treatment. 
Those in need of treatment include those already with the 
condition or disorder as well as those prone to have the 
condition or disorder or those in which the condition or 
40 disorder is to be prevented. 
The phrase "therapeutically effective amount" means an 
amount of a compound of the subject technology that (i) 
treats, inhibits, or prevents the particular disease, condition, 
or disorder, (ii) attenuates, ameliorates, or eliminates one or 
45 more symptoms of the particular disease, condition, or 
disorder, or (iii) prevents or delays the onset of one or more 
symptoms of the particular disease, condition, or disorder 
described herein. In the case of cancer, the therapeutically 
effective amount of the drug may be reduce the number of 
50 cancer cells; reduce the tumor size; inhibit (i.e., slow to 
some extent and preferably stop) cancer cell infiltration into 
peripheral organs; inhibit (i.e., slow to some extent and 
preferably prevent or stop) tumor metastasis; inhibit, to 
some extent, tumor growth; and/or relieve to some extent 
55 one or more of the symptoms associated with the cancer. To 
the extent the drug may prevent growth, inhibit, and/or kill 
existing cancer cells, it may be cytostatic and/or cytotoxic. 
For cancer therapy, efficacy can be measured, for example, 
by assessing the time to disease progression (TTP) and/or 
60 determining the response rate (RR). 
The terms "cancer" and "cancerous" refer to or describe 
the physiological condition in mammals that is typically 
characterized by unregulated cell growth. A "tumor" com­
prises one or more cancerous cells. Examples of cancer 
65 include, but are not limited to, carcinoma, lymphoma, blas­
toma, sarcoma, and leukemia or lymphoid malignancies. 
More particular examples of such cancers include squamous 
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cell cancer (e.g., epithelial squamous cell cancer), lung 
cancer including small-cell lung cancer, non-small cell lung 
cancer ("NSCLC"), adenocarcinoma of the lung and 
squamous carcinoma of the lung, cancer of the peritoneum, 
hepatocellular cancer, gastric or stomach cancer including 
gastrointestinal cancer, pancreatic cancer, glioblastoma, cer­
vical cancer, ovarian cancer, liver cancer, bladder cancer, 
hepatome, breast cancer, colon cancer, rectal cancer, col­
orectal cancer, endometrial or uterine carcinoma, salivary 
gland carcinoma, kidney or renal cancer, prostate cancer, 
vulva! cancer, thyroid cancer, hepatic carcinoma, anal car­
cinoma, penile carcinoma, as well as head and neck cancer. 
10 
Synthesis 
The compounds of the subject technology, including 
compounds of Formula (I) to Formula (II), may be prepared 
by methods disclosed herein or any other method known in 
the art. One of ordinary skill in the art will know how to 
modify procedures to obtain the analogs of the subject 
technology. In addition, compounds may be prepared using 
the methods described below and in Example 1 or modified 
versions thereof. 
10 
FIG. 1 is a schematic of the general synthesis of certain 
arylquinoline compounds of the subject technology. Addi­
tional arylquinoline compounds of the subject technology 
can be made by similar methods or known synthetic proce­
dures known in the art in light of the subject technology. 
The subject technology also encompasses biotinylated 
15 derivatives of the arylquinoline compounds. Such bioti­
nylated derivatives are useful in identifying the molecular 
target for these agents. Compounds encompassed by For­
mulas (I), (II) and (II) can be synthesized and converted to 
The term "prodrug" as used in this application refers to a 
precursor or derivative form of a compound of the disclosure 
that may be less cytotoxic to cells compared to the parent 
compound or drug and is capable of being enzymatically or 
hydrolytically activated or converted into the more active 
parent form. The prodrugs of this disclosure include, but are 
not limited to, phosphate-containing prodrugs, thiophos- 20 
phate-containing prodrugs, sulfate-containing prodrugs, 
peptide-containing prodrugs, D-amino acid-modified prod­
rugs, glycosylated prodrugs, �-lactam-containing prodrugs, 
optionally substituted phenoxyacetamide-containing prod­
rugs, optionally substituted phenylacetamide-containing 25 
prodrugs, 5-fluorocytosine and other 5-fluorouridine prod­
rugs which can be converted into the more active cytotoxic 
free drug. 
biotinylated derivatives. 
In certain embodiments of the subject technology, the 
arylquinoline compounds of the disclosure, or a pharmaceu­
tically acceptable salt, solvate, hydrate or prodrug thereof, 
inhibit the growth or spread of cancer cells by promoting 
apoptosis in them. 
Metabolites of Compounds of the Disclosure 
Also falling within the scope of this disclosure are the in 
vivo metabolic products of Formulas (I) to (II) described 
herein. Such products may result for example from the 
oxidation, reduction, hydrolysis, amidation, deamidation, A "metabolite" is a product produced through metabolism 
in the body of a specified compound or salt thereof. Metabo­
lites of a compound may be identified using routine tech­
niques known in the art and their activities determined using 
tests such as those described herein. Such products may 
result for example from the oxidation, reduction, hydrolysis, 
amidation, deamidation, esterification, deesterification, 
enzymatic cleavage, and the like, of the administered com­
pound. 
The term "alkyl" is art-recognized, and includes saturated 
aliphatic groups, including straight-chain alkyl groups, 
branched-chain alkyl groups, cycloalkyl (alicyclic) groups, 
alkyl substituted cycloalkyl groups, and cycloalkyl substi­
tuted alkyl groups. In certain embodiments, a straight chain 
or branched chain alkyl has about 30 or fewer carbon atoms 
in its backbone (e.g., C1-C30 for straight chain, C3-C30 for 
branched chain), and alternatively, about 20 or fewer. Like­
wise, cycloalkyls have from about 3 to about 10 carbon 
atoms in their ring structure, and alternatively about 5, 6 or 
7 carbons in the ring structure. The term "alkyl" as used 
herein also includes halo-substituted alkyls. 
Unless the number of carbons is otherwise specified, 
"lower alkyl" refers to an alkyl group, as defined above, but 
having from one to about ten carbons (C1 -C10), e.g., from 
one to about six carbon atoms (C1 -C6) in its backbone 
structure. Likewise, "lower alkenyl" "loweralkyl, "lower 
amino", "lower alkynyl", etc. have similar chain lengths. 
Therapeutic Agents 
Disclosed herein are arylquinoline compounds, i.e., com­
pounds of Formula (I), (II) and (III), and their use in treating 
cancer cells or in treating, or inhibiting metastatic cells. 
Such compounds of the subject technology are Par-4 secre­
tagogues, i.e., promote secretin of Par-4 from cells, which 
promote apoptosis in cancer cells or metastatic cells. Such 
compounds are described as "arylquins" as a general 
descriptor of Par-4 secretagogues. Thus, in an embodiment, 
the compounds of the subject technology are useful in 
treating cancers including, but not limited to, colorectal 
cancer, liver cancer, breast cancer and lung cancer. 
30 esterification, deesterification, enzymatic cleavage, and the 
like, of the administered compound. 
Accordingly, the disclosure includes metabolites of com­
pounds of Formulas (I) to (II), including compounds pro­
duced by a process comprising contacting a compound of 
35 this disclosure with a mammal for a period of time sufficient 
to yield a metabolic product thereof. 
Metabolite products typically are identified by preparing 
a detectably labeled, for example a radio labeled ( e.g., C or 
H isotope) compound of the disclosure, administering it 
40 parenterally in a detectable dose ( e.g., greater than about 0.5 
mg/kg) to an animal such as rat, mouse, guinea pig, monkey, 
or to man, allowing sufficient time for metabolism to occur 
(typically about 30 seconds to 30 hours) and isolating its 
conversion products from the urine, blood or other biologi-
45 cal samples. These products are easily isolated since they are 
detectably labeled (others are isolated by the use of anti­
bodies capable of binding epitopes surviving in the metabo­
lite). The metabolite structures are determined in conven­
tional fashion, e.g., by MS, LC/MS or NMR analysis. In 
50 general, analysis of metabolites is done in the same way as 
conventional drug metabolism studies, which are well 
known to those skilled in the art. The metabolite products, 
so long as they are not otherwise found in vivo, are useful 
in diagnostic assays for therapeutic dosing of the compounds 
55 of the disclosure. 
Prodrugs of the Compounds of the Disclosure 
In addition to compounds of the subject technology, the 
disclosure also includes pharmaceutically acceptable prod­
rugs of such compounds. Prodrugs include compounds 
60 wherein an amino acid residue, or a polypeptide chain of two 
or more (e.g., two, three or four) amino acid residues, is 
covalently joined through an amide or ester bond to a free 
amino, hydroxy or carboxylic acid group of a compound of 
the subject technology. The amino acid residues include but 
65 are not limited to the 20 naturally occurring amino acids 
commonly designated by three letter symbols and also 
includes phosphoserine, phosphothreonine, phosphotyro-
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sine, 4-hydroxyproline, hydroxyzine, demosine, isodem­
osine, gamma-carboxyglutamate, hippuric acid, octahy­
droindole-2-carboxylic acid, statine, 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid, penicillamine, 
omithine, 3-methylhistidine, norvaline, beta-alanine, 
gamma-aminobutyric acid, citrulline, homocysteine, homo­
serine, methyl-alanine, para-benzoylphenylalanine, phenyl­
glycine, propargylglycine, sarcosine, methionine sulfone 
and tert-butylglycine. 
For additional examples of prodrug derivatives, see, for 
example, a) Design of Prodrugs, edited by H. Bundgaard, 
(Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 
309-396, edited by K. Widder, et al. (Academic Press, 1985);
b) A Textbook of Drug Design and Development, edited by
Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design
and Application of Prodrugs," by H. Bundgaard p. 113-191
(1991); c) H. Bundgaard, Advanced Drug Delivery Reviews,
8:1-38 (1992); d) H. Bundgaard, et al., Journal of Pharma­
ceutical Sciences, 77:285 (1988); and e) N. Kakeya, et al.,
Chem. Phann. Bull., 32:692 (1984), each of which is spe­
cifically incorporated herein by reference.
Pharmaceutical Compositions 
The subject technology also encompasses pharmaceutical 
compositions comprising at least one arylquinoline com­
pounds, e.g., one or more compounds of Formula (I), (II), 
and/or Formula (III) and/or one or more pharmaceutically 
acceptable salts thereof, in combination with a pharmaceu­
tical carrier or excipient. In one embodiment of the subject 
technology, the pharmaceutical compositions comprise an 
effective amount of at least one such compound. In another 
embodiment, the pharmaceutical composition comprises 
one or more compounds of Formula (III), e.g., Arylquin-1, 
and a pharmaceutically acceptable carrier. 
While it may be possible for compounds of the subject 
technology to be administered as the raw chemical, it is 
preferable to present them as a pharmaceutical composition. 
According to a further aspect, the subject technology pro­
vides a pharmaceutical composition comprising a compound 
or mixture of compounds of Formula (I) to Formula (II) or 
12 
agents, lubricants, binders, disintegrating agents and the like 
may be used. If desired, the tablets or capsules may be 
enteric-coated or sustained release by standard techniques. 
In one embodiment, the compositions are prepared with 
carriers that will protect the active compound(s) against 
rapid elimination from the body, such as a controlled release 
formulation, including implants and microencapsulated 
delivery systems. Biodegradable, biocompatible polymers 
can be used, such as ethylene vinyl acetate, polyanhydrides, 
10 
polyglycolic acid, collagen, polyorthoesters, and polylactic 
acid. Methods for preparation of such formulations will be 
apparent to those skilled in the art. 
The pharmaceutically acceptable carrier may take a wide 
15 
variety of forms, depending on the route desired for admin­
istration, for example, oral or parenteral (including intrave­
nous). Carriers such as starches, sugars, microcrystalline 
cellulose, diluents, granulating agents, lubricants, binders 
and disintegrating agents may be used in the case of oral 
20 solid preparations such as powders, capsules and caplets, 
with the solid oral preparation being preferred over the 
liquid preparations. Preferred solid oral preparations are 
tablets or capsules, because of their ease of administration. 
If desired, tablets may be coated by standard aqueous or 
25 nonaqueous techniques. Oral and parenteral sustained 
release dosage forms may also be used. 
Liposomal suspensions may also be pharmaceutically 
acceptable carriers. These may be prepared according to 
methods known to those skilled in the art. For example, 
30 liposomal formulations may be prepared by dissolving 
appropriate lipid(s) in an inorganic solvent that is then 
evaporated, leaving behind a thin film of dried lipid on the 
surface of the container. An aqueous solution of the active 
compound is then introduced into the container. The con-
35 tainer is then swirled by hand to free lipid material from the 
sides of the container and to disperse lipid aggregates, 
thereby forming the liposomal suspension. Other methods of 
preparation well known by those of ordinary skill may also 
be used in this aspect of the subject technology. 
In an embodiment, the composition of the subject tech-
nology enables sustained, continuous delivery of a com­
pound of Formula (I) to Formula (II) or a pharmaceutically 
acceptable salt, solvate, hydrate, prodrug or metabolite 
thereof, to tissues adjacent to or distant from an adminis-
a pharmaceutically acceptable salt, solvate, hydrate, prodrug 40 
or metabolite thereof, together with one or more pharma­
ceutical carrier, excipient or additive and optionally one or 
more other therapeutic ingredients. The carrier(s) must be 
"acceptable" in the sense of being compatible with the other 
ingredients of the formulation and not deleterious to the 
recipient thereof. The term "pharmaceutically acceptable 
carrier" includes vehicles and diluents. 
45 tration site. The biologically-active agent is capable of 
providing a local or systemic biological, physiological or 
therapeutic effect. For example, a compound of Formula (I) 
to Formula (II) or a pharmaceutically acceptable salt, sol­
vate, hydrate, prodrug or metabolite thereof, may act to kill 
To prepare the pharmaceutical compositions, a therapeu­
tically effective amount of one or more of the arylquinoline 
compounds according to the subject technology may be 
intimately admixed with a pharmaceutically acceptable car­
rier according to conventional pharmaceutical compounding 
techniques to produce a dose. A carrier may take a wide 
variety of forms depending on the form of preparation 
desired for administration, e.g., oral, topical or parenteral, 
including gels, creams ointments, lotions and time released 
implantable preparations, among numerous others. In pre­
paring pharmaceutical compositions in oral dosage form, 
any of the usual pharmaceutical media may be used. Thus, 
for liquid oral preparations such as suspensions, elixirs and 
solutions, suitable carriers and additives including water, 
glycols, oils, alcohols, flavoring agents, preservatives, col­
oring agents and the like may be used. For solid oral 
preparations such as powders, tablets, capsules, and for solid 
preparations such as suppositories, suitable carriers and 
additives including starches, sugar carriers, such as dextrose, 
mannitol, lactose and related carriers, diluents, granulating 
50 cancer cells, or cancer stem cells or to control or suppress 
tumor growth or metastasis, among other functions. 
Formulations and Dosages for Administration 
Pharmaceutical formulations based upon arylquinoline 
compounds of the subject technology comprise at least one 
55 of the compounds of Formula (I) to Formula (III) or a 
pharmaceutically acceptable salt, solvate, hydrate, prodrug 
or metabolite thereof, in a therapeutically effective amount 
for treating neoplasia, cancer and other diseases and condi­
tions that may benefit from induced Par-4 secretion, option-
60 ally in combination with a pharmaceutically acceptable 
additive, carrier and/or excipient. One of ordinary skill in the 
art will recognize that a therapeutically effective amount of 
one of more compounds according to the subject technology 
will vary with the condition to be treated, its severity, the 
65 treatment regimen to be employed, the pharmacokinetics of 
the agent used, as well as the patient (animal or human) 
treated. 
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Exemplary formulations are well known to those skilled 
in the art, and general methods for preparing them are found 
in any standard pharmacy school textbook, for example, 
Remington: THE SCIENCE AND PRACTICE OF PHAR­
MACY, 21st Ed., Lippincott. The formulations of the subject 
technology may conveniently be presented in unit dosage 
form and may be prepared by any of the methods well 
known in the art of pharmacy. All methods include the step 
14 
In certain embodiments of the subject technology, the 
arylquinoline compounds are formulated as admixture with 
a pharmaceutically acceptable carrier, excipient or additive. 
In certain pharmaceutical dosage forms, the pro-drug form 
of the compounds may be preferred. One of ordinary skill in 
the art will recognize how to readily modify the present 
compounds to pro-drug forms to facilitate delivery of active 
compounds to a targeted site within the host organism or 
patient. The mutineer also will take advantage of favorable of bringing into association a compound or a pharmaceuti­
cally acceptable salt or solvate thereof ("active ingredient") 
with the carrier which constitutes one or more accessory 
ingredients. In general, the formulations are prepared by 
uniformly and intimately bringing into association the active 
ingredient with liquid carriers or finely divided solid carriers 
or both and then, if necessary, shaping the product into the 
desired formulation. Oral formulations are well known to 
those skilled in the art, and general methods for preparing 
them are found in any standard pharmacy school textbook, 
for example, Remington: THE SCIENCE AND PRACTICE 
OF PHARMACY, 21st Ed., the entire disclosure of which is 
incorporated herein by reference. 
10 pharmacokinetic parameters of the pro-drug forms, where 
applicable, in delivering the present compounds to a targeted 
site within the host organism or patient to maximize the 
intended effect of the compound. 
Pharmaceutical compositions containing any of the com-
15 pounds of Formula (I) to Formula (III) or a pharmaceutically 
acceptable salt, solvate, hydrate, prodrug or metabolite 
thereof, may be conveniently presented in unit dosage form 
and prepared by any of the methods well known in the art of 
pharmacy. Preferred unit dosage formulations are those 
The concentration of active compound of the subject 
technology, i.e., at least one of the compounds of Formula (I) 
20 containing an effective dose, or an appropriate fraction 
thereof, of the active ingredient, or a pharmaceutically 
acceptable salt thereof. The magnitude of a prophylactic or 
therapeutic dose typically varies with the nature and severity 
of the condition to be treated and the route of administration. to Formula (III) or a pharmaceutically acceptable salt, 
solvate, hydrate, prodrug or metabolite thereof, in the drug 25 
composition will depend on absorption, distribution, inacti­
vation, and excretion rates of the drug as well as other 
factors known to those of skill in the art. It is to be noted that 
dosage values will also vary with the severity of the condi­
tion to be alleviated. The composition may be administered 
The dose, and perhaps the dose frequency, will also vary 
according to the age, body weight and response of the 
individual patient. In general, the total daily dose (in single 
or divided doses) ranges from about 0.0001 mg per day to 
about 2 mg per day, or about 0.1 mg per day to about 100 
at once, or may be divided into a number of smaller doses 
to be administered at varying intervals of time. 
Oral compositions will generally include an inert diluent 
or an edible carrier. They may be enclosed in gelatin­
capsules or compressed into tablets. For the purpose of oral 
therapeutic administration, the active compound or its pro­
drug derivative can be incorporated with excipients and used 
30 mg per day, or about 10 mg per day to about 1000 mg per 
day, or from about 100 mg per day to about 10000 mg per 
day, or from about 5 mg per day to about 100 mg per day, 
to about 50 mg per day or to about 250 mg per day. In some 
embodiments, the total daily dose may range from about 1 
in the form of tablets, troches, or capsules. Pharmaceutically 
compatible binding agents, and/or adjuvant materials can be 
included as part of the composition. 
35 mg per day to about 50 mg per day, or about 10 mg per day 
to about 500 mg per day. It is further recommended that 
children, patients over 65 years old, and those with impaired 
renal or hepatic function, initially receive low doses, and 
that the dosage be titrated based on individual responses 
40 and/or blood levels. It may be necessary to use dosages 
outside these ranges in some cases, as will be apparent to 
those in the art. Further, it is noted that the clinician or 
treating physician knows how and when to interrupt, adjust 
The tablets, pills, capsules, troches and the like can 
contain any of the following non-limiting ingredients, or 
compounds of a similar nature: a binder such as microcrys­
talline cellulose, gum tragacanth or gelatin; an excipient 
such as starch or lactose, a dispersing agent such as alginic 45 
acid or corn starch; a lubricant such as magnesium stearate; 
a glidant such as colloidal silicon dioxide; a sweetening 
agent such as sucrose or saccharin; or a flavoring agent such 
as peppermint, methyl salicylate, or fruit flavoring. When 
the dosage unit form is a capsule, it can contain, in addition 50 
to any of the above, a liquid carrier such as fatty oil. In 
addition, dosage unit forms can contain various other mate­
rials which modify the physical form of the dosage unit, for 
example, coatings of sugar, shellac, or enteric agents. 
The tablets, for example, may optionally be coated or 55 
scored and may be formulated so as to provide sustained, 
delayed or controlled release of the active ingredient therein. 
Oral and parenteral sustained release drug delivery systems 
are well known to those skilled in the art, and general 
methods of achieving sustained release of orally or parent- 60 
erally administered drugs are found, for example, in Rem­
ington: The Science and Practice of Pharmacy, 21st Ed. 
The active compound may also be administered as a 
component of an elixir, suspension, syrup, wafer or the like. 
Syrup may contain, in addition to the active compounds, 65 
sucrose or fructose as a sweetening agent and certain pre­
servatives, dyes and colorings and flavors. 
or terminate therapy in conjunction with individual patient's 
response. 
Alternatively, the maximum safe starting dose of the 
compounds of the subject technology for use in initial 
clinical trials in adults may be determined by following, for 
example, the FDA guidelines for estimating maximum safe 
dosage. These guidelines provide guidance for using the 
dosages used in animal studies to extrapolate safe dosage for 
use in human trials. See Guidance for Industry, Estimating 
the Maximum Safe Starting Dose in Initial Clinical Trials for 
Therapeutics in Adult Healthy Volunteers, Food and Drug 
Administration, Center for Drug Evaluation and Research 
(CDER), July 2005. 
In an embodiment, the amount of compound included 
within therapeutically effective formulations of the subject 
technology is an effective amount for treating cancer or 
cancer metastasis by promoting apoptosis in the cancer cells. 
In general, a therapeutically effective amount of the present 
preferred compound in dosage form usually ranges from 
slightly less than about 0.0001 mg/kg to about 0.003 mg/kg 
or about 0.0025 mg/kg to about 2.5 g/kg, and in certain 
embodiments about 0.025 mg/kg to about 5 mg/kg or about 
0.25 mg/kg to about 100 mg/kg or about 2.5 mg/kg to about 
250 mg/kg or about 25 mg/kg to about 500 mg/kg or 
US 9,873,670 B2 
15 
considerably more, depending upon the compound used, the 
condition being treated and the route of administration, 
although exceptions to this dosage range may be contem­
plated by the subject technology. In some embodiments, 
arylquinoline compounds of the subject technology are 
administered in amounts ranging from about 0.0001 mg/kg 
to about 1000 mg/kg. 
16 
administration includes intravenous, intraperitoneal, subcu­
taneous, intramuscular, intratumoral, transepithelial, nasal, 
intrapulmonary, intrathecal, rectal and topical modes of 
administration. Parenteral administration may be by con­
tinuous infusion over a selected period of time 
Alternatively, the compounds of this disclosure may be 
incorporated into formulations for any route of administra­
tion including for example, oral, topical and parenteral 
including intravenous, intramuscular, eye or ocular, intrap­
eritoneal, intrabuccal, transdermal and in suppository form. 
Of course, one of ordinary skill in the art may modify the 
formulations within the teachings of the specification to 
provide numerous formulations for a particular route of 
administration without rendering the pharmaceutical com-
The active compound of the subject technology, i.e., at 
least one of the compounds of Formula (I), (II), or (II) or a 
pharmaceutically acceptable salt, solvate, hydrate, prodrug 10 
or metabolite thereof, is included in the pharmaceutically 
acceptable carrier or diluent in an amount sufficient to 
deliver to a patient a therapeutically effective amount for the 
desired indication, without causing serious toxic effects in 
the patient treated. 
In certain embodiments, the active compound is conve­
niently administered in any suitable unit dosage form, 
including but not limited to one containing 1 to 3000 mg, 
preferably 5 to 500 mg of active ingredient per unit dosage 
form. An oral dosage of 10-250 mg is usually convenient. 20 
15 positions unstable or compromising their therapeutic activ­
ity. It is also well within the mutineer's skill to modify the 
route of administration and dosage regimen of a particular 
compound in order to manage the pharmacokinetics of the 
The actual dosage amount of a composition of the subject 
technology administered to a patient or subject can be 
determined by physical and physiological factors such as 
body weight, severity of condition, the type of disease being 
treated, previous or concurrent therapeutic interventions, 25 
idiopathy of the patient and on the route of administration. 
The practitioner responsible for administration will, in any 
event, determine the concentration of active ingredient( s) in 
present compounds for maximum beneficial effect to the 
patient. 
Methods of Treatment 
In an embodiment, the subject technology is directed to 
methods for treating cancer or treating and/or inhibiting 
cancer metastasis in a subject comprising administering to 
the subject an effective amount of a compound or compo­
sition of one or more compounds of Formula (I), (II), and/or 
Formula (III) and/or one or more pharmaceutically accept­
able salt, solvate, hydrate, prodrug or metabolite thereof. 
For example, the subject technology contemplates meth-a composition and appropriate dose(s) for the individual 
subject. 30 ods of treating various cancers and complications thereof. 
In certain embodiments, pharmaceutical compositions 
may comprise, for example, at least about 0.1 % of an active 
compound, i.e., at least one of the compounds of Formula 
(I), (II), (III) or a pharmaceutically acceptable salt, solvate, 
hydrate, prodrug or metabolite thereof. In other embodi- 35 
ments, the active compound may comprise between about 
1 % to about 75% of the weight of the unit, or between about 
5% to about 50%, for example, and any range derivable 
therein. In other non-limiting examples, a dose may also 
comprise about 0.001 microgram/kg/body weight to about 5 40 
microgram/kg/body weight, or about 1 microgram/kg/body 
weight to about 50 microgram/kg/body weight, or about 20 
milligram/kg/body weight to about 150 milligram/kg/body 
weight, or about 100 milligram/kg/body weight to about 300 
milligram/kg/body weight, or about 200 milligram/kg/body 45 
weight to about 1000 milligram/kg/body weight or more per 
administration, and any range derivable therein. In non­
limiting examples of a derivable range from the numbers 
listed herein, a range of about 1 microgram/kg/body weight 
to about 50 milligram/kg/body weight, or from about 20 50 
microgram/kg/body weight to about 500 milligram/kg/body 
weight, etc., can be administered. 
Route of Administration 
In accordance with the methods of the subject technology, 
the described arylquinoline compounds of the subject tech- 55 
nology or a pharmaceutically acceptable salt, solvate, 
hydrate or prodrug thereof, may be administered to a subject 
in a variety of forms depending on the selected route of 
administration, as will be understood by those skilled in the 
art. The active compound of the disclosure may be admin- 60 
istered, for example, by oral, parenteral (including subcuta­
neous, intradermal, intramuscular, intravenous, intraperito­
neal, intratumoral and intraarticular, intratumoral, 
transepithelial, nasal, intrapulmonary, intrathecal), buccal, 
sublingual, nasal, rectal, topical (including dermal, buccal, 65 
sub lingual and intraocular ), or transdermal administration as 
well as those for administration by inhalation. Parenteral 
More particularly, the subject technology relates to methods 
for inhibiting the growth of benign and malignant cancer, 
including a malignant tumor or cancer comprising exposing 
the tumor to an inhibitory or therapeutically effective 
amount or concentration of at least one arylquinoline com­
pound or pharmaceutically acceptable salts or pharmaceu-
tically acceptable composition thereof. Treatment of internal 
malignancies such as eye or ocular cancer, rectal cancer, 
colon cancer, cervical cancer, prostate cancer, breast cancer, 
liver cancer and bladder cancer, and age-related cancer 
among numerous others are contemplated by the subject 
technology. 
Accordingly, the compounds and/or compositions of the 
subject technology are useful for treating animals, and in 
particular, mammals, including humans, as patients. Thus, 
humans and other animals, and in particular, mammals, 
suffering from cancer can be treated by administering to the 
patient an effective amount of one or more of the arylqui­
noline compounds according to the subject technology, or its 
derivative or a pharmaceutically acceptable salt thereof, 
optionally in a pharmaceutically acceptable carrier or 
diluent, either alone, or in combination with other known 
pharmaceutical agents ( depending upon the disease to be 
treated). Treatment according to the subject technology can 
also be by administration of the compounds and/or compo­
sitions of the subject technology in conjunction with other 
conventional cancer therapies, such as radiation treatment or 
surgery or administration of other anti-cancer agents. 
In certain embodiments, the subject technology can find 
application in the treatment of any disease for which deliv­
ery of a therapeutic arylquinoline compound or a pharma­
ceutically acceptable salt, solvate, hydrate, prodrug or 
metabolite thereof to a cell or tissue of a subject is believed 
to be of therapeutic benefit. Examples of such diseases 
include hyperproliferative diseases and quiescent malignant 
diseases. In particular embodiments, the disease is a hyper-
proliferative disease, such as cancer of solid tissues or blood 
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cells. Quiescent malignant diseases that can be treated by an 
arylquinoline compound of the subject technology or a 
pharmaceutically acceptable salt, solvate, hydrate, prodrug 
or metabolite thereof include, for example, chronic lympho­
cytic leukemia. 
18 
triethiylenethiophosphoramide and trimethylolomelamine; 
acetogenins (especially bullatacin and bullatacinone); a 
camptothecin (including the synthetic analogue topotecan); 
bryostatin; callystatin; CC-1065 (including its adozelesin, 
carzelesin and bizelesin synthetic analogues); cryptophycins 
(particularly cryptophycin 1 and cryptophycin 8); dolastatin; 
duocarmycin (including the synthetic analogues, KW-2189 
and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin; 
spongistatin; nitrogen mustards such as chlorambucil, chlo­
maphazine, cholophosphamide, estramustine, ifosfamide, 
mechlorethamine, mechlorethamine oxide hydrochloride, 
melphalan, novembichin, phenesterine, prednimustine, tro­
fosfamide, uracil mustard; nitrosureas such as carmustine, 
chlorozotocin, fotemustine, lomustine, nimustine, and ran-
For example, a compound or composition of an arylqui­
noline compound of the subject technology or a pharma­
ceutically acceptable salt, solvate, hydrate, prodrug or 
metabolite thereof can be administered to treat a hyperpro­
liferative disease. The hyperproliferative disease may be 10 
cancer, leiomyomas, adenomas, lipomas, hemangiomas, 
fibromas, pre-neoplastic lesions (such as adenomatous 
hyperplasia and prostatic intraepithelial neoplasia), carci­
noma in situ, oral hairy leukoplakia, or psoriasis, for 
example. 
The cancer may be a solid tumor, metastatic cancer, or 
non-metastatic cancer. In certain embodiments, the cancer 
may originate in the bladder, blood, bone, bone marrow, 
brain, breast, colon, esophagus, duodenum, small intestine, 
large intestine, colon, rectum, anus, gum, head, kidney, liver, 20 
lung, nasopharynx, neck, ovary, prostate, skin, stomach, 
testis, tongue, or uterus. In certain embodiments, the cancer 
15 inmustine; antibiotics such as the enediyne antibiotics (e.g., 
calicheamicin, especially calicheamicin ganimall and cali­
cheamicin omegall; dynemicin, including dynemicin A; 
bisphosphonates, such as clodronate; an esperamicin; as 
well as neocarzinostatin chromophore and related chro­
moprotein enediyne antiobiotic chromophores, aclacino­
mysins, actinomycin, authramycin, azaserine, bleomycins, 
cactinomycin, carabicin, carminomycin, carzinophilin, 
chromomycinis, dactinomycin, daunorubicin, detorubicin, 
6-diazo-5-oxo-L-norleucine, doxorubicin (including mor-
is ovarian cancer. In particular aspects, the cancer may be a 
chemo-resistant cancer, i.e., refractive forms of cancer, such 
as taxane-resistant or cisplatin resistant cancer. 
In another aspect, the subject technology provides a 
method for promoting secretin of Par-4 in a cell by contact­
ing the cell with an effective amount of an arylquinoline 
compound of the subject technology. In another aspect, there 
25 pholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyr­
rolino-doxorubicin and deoxy doxorubicin), epirubicin, eso­
rubicin, idarubicin, marcellomycin, mitomycins such as 
mitomycin C, mycophenolic acid, nogalamycin, olivomy-
is provided a method for promoting apoptosis in a cancer 30 
cell by contacting the cell with an effective amount of an 
arylquinoline compound of the subject technology. 
Combination Therapy 
The active compounds of the subject technology, i.e., one 
or more compounds of Formula (I) to (III) and/or one or 35 
more pharmaceutically acceptable salt, solvate, hydrate, 
prodrug or metabolite thereof can also be mixed with other 
active materials that do not impair the desired action, or with 
materials that supplement the desired action, such as che­
motherapeutic agents, NF-KB inhibitors, other anticancer 40 
agents, and in certain instances depending upon the desired 
therapy or target, antibiotics, antifungals, antinflammatories, 
antiviral compounds or other agents having a distinct phar­
macological effect. 
The methods and compositions of the subject technology 45 
further provide combination therapies which can enhance 
the therapeutic or protective effect of the compounds of the 
subject technology, and/or increase the therapeutic effect of 
another anti-cancer. Therapeutic and prophylactic methods 
and compositions can be provided in a combined amount 50 
effective to achieve the desired effect, such as the killing of 
a cancer cell and/or the inhibition of cancer metastasis. This 
process may involve contacting the cells with, for example, 
cins, peplomycin, potfiromycin, puromycin, quelamycin, 
rodorubicin, streptonigrin, streptozocin, tubercidin, uben­
imex, zinostatin, zorubicin; anti-metabolites such as metho-
trexate and 5-fluorouracil (5-FU); folic acid analogues such 
as denopterin, methotrexate, pteropterin, trimetrexate; 
purine analogues such as fludarabine, 6-mercaptopurine, 
thiamiprine, thioguanine; pyrimidine analogues such as 
ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, 
dideoxyuridine, doxifluridine, enocitabine, floxuridine; 
androgens such as calusterone, dromostanolone propionate, 
epitiostanol, mepitiostane, testolactone; anti-adrenals such 
as aminoglutethimide, mitotane, trilostane; folic acid replen­
isher such as frolinic acid; aceglatone; aldophosphamide 
glycoside; aminolevulinic acid; eniluracil; amsacrine; 
bestrabucil; bisantrene; edatraxate; defofamine; demecol­
cine; diaziquone; elformithine; elliptinium acetate; an epoth­
ilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; 
lonidainine; maytansinoids such as maytansine and ansami-
tocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; 
pentostatin; phenamet; pirarubicin; losoxantrone; podoph­
yllinic acid; 2-ethylhydrazide; procarbazine; PSK polysac­
charide complex); razoxane; rhizoxin; sizofiran; spiroger­
manium; tenuazonic acid; triaziquone; 2,2',2"-
trichlorotriethylamine; trichothecenes ( especially T-2 toxin, 
verracurin A, roridin A and anguidine ); urethan; vindesine; 
dacarbazine; mannomustine; mitobronitol; mitolactol; pipo-a therapeutic nucleic acid, such as a chemotherapeutic agent 
or an inhibitor of gene expression, as a second therapy. A 
tissue, tumor, or cell can be contacted with the compounds 
or compositions of the subject technology and one or more 
additional anti-cancer treatment. For example, an additional 
anticancer treatment may include a chemotherapeutic agent, 
an NF-KB inhibitor, an anti-hormonal agent, radiotherapy, 
surgical therapy, or immunotherapy. 
55 broman; gacytosine; arabinoside ("Ara-C"); cyclophosph­
amide; thiotepa; taxoids, e.g., paclitaxel and doxetaxel; 
chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; 
methotrexate; platinum coordination complexes such as 
cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; 
Examples of chemotherapeutic agents include alkylating 
agents such as thiotepa and cyclosphosphamide; alkyl sul­
fonates such as busulfan, improsulfan and piposulfan; aziri­
dines such as benzodopa, carboquone, meturedopa, and 
uredopa; ethylenimines and methylamelamines including 
altretamine, triethy lenemelamine, triety lenephosphoramide, 
60 etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; 
vinorelbine; novantrone; teniposide; edatrexate; daunomy­
cin; aminopterin; xeloda; ibandronate; irinotecan ( e.g., 
CPT-I 1); topoisomerase inhibitor RFS 2000; difluorometl­
hylornithine (DMFO); retinoids such as retinoic acid; 
65 capecitabine; cisplatin (CDDP), carboplatin, procarbazine, 
mechlorethamine, cyclophosphamide, camptothecin, ifosf­
amide, melphalan, chlorambucil, busulfan, nitrosurea, dac-
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tinomycin, daunorubicin, doxorubicin, bleomycin, plicomy­
cin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene, 
estrogen receptor binding agents, taxol, paclitaxel, doc­
etaxel, gemcitabien, navelbine, famesyl-protein tansferase 
inhibitors, transplatinum, 5-fluorouracil, vincristine, vin­
blastine and methotrexate and pharmaceutically acceptable 
salts, acids or derivatives of any of the above. 
20 
days, and/or 1, 2, 3, 4, 5 weeks, and/or 1, 2, 3, 4, 5, 6, 7, 8, 
9, 10, 11, 12 months or more, depending on the condition of 
the patient, such as their prognosis, strength, health, etc. 
Examples of nf-Kb inhibitors include 9-methylstreptimi­
done, n-stearoyl phytosphingosine, 2-(1,8-naphthyridin-2-
yl)-phenol, 5-aminosalicylic acid, cape (caffeic acid phen­
ethylester), diethylmaleate, ethyl 3,4-dihydroxycinnamate, 
helenalin, nf-Kb activation inhibitor ii, nfKb activation 
inhibitor iii, glucocorticoid receptor modulator, cpda, aspi­
rin, ppm-18, pyrrolidinedithiocarbamic acid ammonium 
salt, rocaglamide, sodium salicylate, andrographolide, (±)4- 15 
hydroxynon-2-enal, ps-1145 dihydrochloride, pioglitazone, 
sulindac sulfide, isohelenin, diethyldithiocarbamic acid 
sodium salt trihydrate, curcumin (synthetic), trichodion 
(which can be purchased, e.g., from Santa Cruz Biothech­
nology, Inc. Dallas, Tex.). 
Administration of any compound or therapy of the subject 
technology to a patient will follow general protocols for the 
administration of such compounds, taking into account the 
toxicity, if any, of the agents. Therefore, in some embodi­
ments there is a step of monitoring toxicity that is attribut­
able to combination therapy. It is expected that the treatment 
10 
cycles would be repeated as necessary. It also is contem­
plated that various standard therapies, as well as radiation 
and surgical intervention, may be applied in combination 
with the described therapy. 
Also included in the formulations may be anti-hormonal 
agents that act to regulate or inhibit hormone action on 
tumors such as anti-estrogens and selective estrogen recep-
20 
tor modulators (SERMs ), including, for example, tamoxifen, 
raloxifene, droloxifene, A-hydroxytamoxifen, trioxifene, 25 
keoxifene, LYI 17018, onapristone, and toremifene; aro­
matase inhibitors that inhibit the enzyme aromatase, which 
regulates estrogen production in the adrenal glands, such as, 
for example, 4(5)-imidazoles, aminoglutethimide, megestrol 
acetate, exemestane, formestanie, fadrozole, vorozole, letro- 30 
zole, and anastrozole; and anti-androgens such as flutamide, 
nilutamide, bicalutamide, leuprolide, and goserelin; as well 
In specific aspects, it is contemplated that a standard 
therapy will include chemotherapy, radiotherapy, immuno­
therapy, surgical therapy or gene therapy and may be 
employed in combination with the combination therapy 
described herein. 
Articles of Manufacture 
In another embodiment of the disclosure, an article of 
manufacture, or "kit", containing materials useful for the 
treatment of the diseases and disorders described above is 
provided. In one embodiment, the kit comprises a container 
comprising at least one compound of Formula (I)-(III), 
and/or one or more pharmaceutically acceptable salt, sol-
vate, hydrate, prodrug or metabolite thereof. 
The kit may further comprise a label or package-insert on 
or associated with the container. The term "package insert" 
is used to refer to instructions customarily included in 
commercial packages of therapeutic products, that contain 
information about the indications, usage, dosage, adminis­
tration, contraindications and/or warnings concerning the 
use of such therapeutic products. Suitable containers 
include, for example, bottles, vials, syringes, blister pack, 
etc. The container may be formed from a variety of materials 
such as glass or plastic. The container may hold a compound 
of Formula (I)-(III) or a formulation thereof which is effec-
as troxacitabine (a 1,3-dioxolane nucleoside cytosine ana­
logue); antisense oligonucleotides, particularly those which 
inhibit expression of genes in signaling pathways implicated 35 
in abherant cell proliferation, such as, for example, PKC­
alpha, Ralf and H-Ras; ribozymes such as a VEGF expres­
sion inhibitor and a HER2 expression inhibitor; vaccines 
such as gene therapy vaccines and pharmaceutically accept­
able salts, acids or derivatives of any of the above. 40 tive for treating the condition and may have a sterile access 
port (for example, the container may be an intravenous 
solution bag or a vial having a stopper pierceable by a 
hypodermic injection needle). At least one active agent in 
In an embodiment, a therapeutic formulation or compo­
sition set forth herein, which comprises one or more com­
pounds of Formula (I) to Formula (III) and/or one or more 
pharmaceutically acceptable salt, solvate, hydrate, prodrug 
or metabolite thereof, may be administered before, during, 45 
after or in various combinations relative to a second anti-
the composition is a compound of Formula (I)-(III). The 
label or package insert indicates that the composition is used 
for treating the condition of choice, such as cancer. 
cancer treatment. The administrations may be in intervals 
ranging from concurrently to minutes to days to weeks. In 
embodiments where the arylquinoline containing composi­
tion is provided to a patient separately from an additional 
anti-cancer agent, one would generally ensure that a signifi­
cant period of time did not expire between the time of each 
delivery, such that the two agents would still be able to exert 
an advantageously combined effect on the patient. In such 
instances, it is contemplated that one may provide a patient 
with the inhibitor of gene expression therapy and the anti­
cancer therapy within about 12 to 24 or 72 h of each other 
and, more preferably, within about 6-12 h of each other. In 
some situations it may be desirable to extend the time period 
for treatment significantly where several days (2, 3, 4, 5, 6 
or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between 
respective administrations. 
Within a single day (24-hour period), the patient may be 
given one or multiple administrations of the agent(s). More­
over, after a course of treatment, it is contemplated that there 
is a period of time at which no anti-cancer treatment is 
administered. This time period may last 1, 2, 3, 4, 5, 6, 7 
In an embodiment, the kit includes two separate pharma­
ceutical compositions: one containing a compound of the 
subject technology, and a second pharmaceutical compound. 
50 In another embodiment, an assay or diagnostic kit includes 
a labeled compound of the subject technology and one or 
more reagents necessary for detecting the labeled compound 
upon binding to its target in-vivo or in-vitro. In a related 
embodiment, the kit includes a package insert that describes 
55 the steps necessary for carrying out the detection assay. 
In another embodiment, a kit of the disclosure further 
comprises a needle or syringe, preferably packaged in sterile 
form, for injecting the composition, and/or a packaged 
alcohol pad. Instructions are optionally included for admin-
60 istration of arylquinoline compounds by a clinician or by the 
patient. 
Diagnostic Methods and Diagnostic Probes 
Another aspect of the subject technology provides com­
pounds having general formulas (I)-(III) with a linker moi-
65 ety (hydrophobic linkers, hydrophilic linkers, photo-cleav­
able linkers, redox reaction-cleavable linkers), wherein the 
linker moiety is covalently bonded to a label molecule (a 
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label could be a fluorophor, biotin, different polymer beads 
and different reactive groups). An exemplary biotinylated 
analog is depicted in FIG. 1. 
The compounds of the subject technology when bioti­
nylated provide suitable means for non-radioactive detection 
of target molecules that may play a role in apoptosis 
induction in cells. Therefore, another aspect of the subject 
technology relates to the use of biotinylated arylquinoline 
compounds as a diagnostic reagent for detecting or moni­
toring the presence or levels of vimentin in a complex 10 
protein sample. A complex protein sample contains multiple 
proteins, and may additionally contain other contaminants. 
Non-limiting examples of a complex protein sample include 
tumor tissues, biopsy, serum and cell extracts. 
In one embodiment, the subject technology relates to a 15 
method of detecting, monitoring or analyzing the levels of 
vimentin in a complex protein sample, said method com­
prising adding a labeled compound of Formula (I)-(III) to 
said complex protein mixture under conditions whereby said 
labeled compound covalently conjugates to vimentin; iso- 20 
lating the conjugated vimentin by a suitable affinity-based 
separation method, removing unbound proteins, detecting 
the level of vimentin following the separation. In a related 
embodiment, the detection can be accomplished by measur­
ing a fluorescence signal emitted from the compound of 25 
Formula (I)-(III). In another related embodiment, the detec­
tion can be accomplished by measuring a fluorescence signal 
emitted from a label bound via a linker to the compound of 
Formula (I)-(III). The detection step can also be accom­
plished using various analytical procedures that known to 30 
the artisan for separating and analyzing complex protein 
mixtures. These analytical procedures include chromato­
graphic methods such as HPLC, FPLC, ion exchange, size 
exclusion, mass spectrometry, and the like. 
The linker moiety that can be used to attach a detectable 35 
label to the compounds of the subject technology can be any 
of the linkers shown in FIG. 1. Alternatively, the linker 
moiety comprises a repeating alkyleneoxy structure (poly­
ethylene glycols, or "PEG"). Thus, one of skill in the art can 
select the linker moiety of the compounds of the subject 40 
technology in order to provide additional specificity of them 
for vimentin. 
In an embodiment, it is desirable to have a detectable label 
associated with a compound of the subject technology to 
allow the compound-vimentin complex to be captured and 45 
washed free of other components of the reaction mixture. 
The label will generally be under about 1 kDa. Biotin is a 
conventional label or ligand, particularly analogs such as 
dethiobiotin and deiminobiotin, which can be readily dis­
placed from streptavidin by biotin. However, any small 50 
molecule will suffice that can be captured and released under 
convenient conditions. 
Affinity purification of biological molecules, for example 
proteins, is known in the art and allows the purification of 
molecules by exploiting the binding affinity of the target 55 
molecule for a molecular binding partner. Examples of 
affinity purification methods are fusion tag protein purifica­
tion, avidin-biotin system, pull-down assay and the like. 
Drug Screening Assays 
In another aspect, the subject technology provides assays 60 
for screening test compounds that interfere with vimentin 
binding to PAR-4 or which cause release of vimentin-bound 
PAR-4. In a typical assay, cells, such as HEL cells, are 
seeded onto an appropriate support, such as 60-mm plates 
containing supplemented growth medium ( e.g., supple- 65 
mented with 0.1 % serum) at a desired confluency, such as 
40-70% confluency, and treated with the test compound
22 
( e.g., 500 nM) or control vehicle. The cells are allowed to 
grow for a period of time, such as 24 hours, after which the 
conditioned medium (CM) is concentrated (e.g., concen­
trated 30x to 100 µl using Millipore tubes (Ami con Ultra 
centrifugal filters, Ultracel-1 OK) by 15 min centrifugation at 
4500 rpm). The concentrated CM is then subjected to 
co-immunoprecipitation using detectably labeled PAR-4 and 
vimentin antibodies in the presence of various concentra­
tions of purified PAR-4 and the precipitated proteins are 
resolved by SDS-PAGE and analyzed by Western blot 
analysis. The amount of immunoprecipitated PAR-4-vimen­
tin complex is compared to that of control samples. For 
example, chemiluminescent signals may be quantified in the 
BIO-RAD Molecular Imager ChemiDoc XRS+Imaging sys­
tem using Quantity One software. Induction of Par-4 secre­
tion by the test drug ( e.g., 500 nM), as judged by this 
Western blot analysis procedure, will indicate dissociation of 
Par-4 from vimentin. Additionally, experiments can be 
undertaken to determine whether the test compound disrupts 
the interaction between vimentin and Par-4 using any test 
drug that shows elevated secretion of Par-4 by Western blot 
analysis or other such assay. For such experiments, cells may 
be treated with the test drug ( e.g., 500 nM) or vehicle for an 
appropriate period of time, such as 24 hours, and then cell 
lysates are prepared and subjected to immunoprecipitation 
using an appropriate amount of a Par-4 antibody, vimentin 
antibody or control IgG antibody by using any standard 
immunoprecipitation procedure. Following immunosup­
pression, the complexes are resolved, preferably by Western 
blot analysis as described above. If the drug inhibits the 
binding of Par-4 to vimentin, it will be reflected in the lack 
of co-immunoprecipitation of Par-4 with the vimentin anti­
body, and co-immunoprecipitation of vimentin with the 
Par-4 antibody. 
EXAMPLES 
The following examples are intended to further illustrate 
certain preferred embodiments of the disclosure and are not 
limiting in nature. Those skilled in the art will recognize, or 
be able to ascertain, using no more than routine experimen­
tation, numerous equivalents to the specific substances and 
procedures described herein. 
Materials and Methods 
The following materials and methods were used for the 
experiments described herein. 
Chemistry: Nutlin-3a, an inhibitor of MDM2 that is 
reported to bind directly to MDM2, release, stabilize and 
activate p53, was acquired from Cayman Chemical Com­
pany. Brefeldin A, N-benzyloxycarbonyl-Val-Ala-Asp(O­
Me) fluoromethyl ketone (zVAD-fmk) and other chemicals 
were purchased from Sigma Aldrich or Fisher Scientific or 
were synthesized according to literature procedures. The 
synthesis of Arylquin 1, which utilized 4-(N,N-dimethyl­
amino )-2-aminobenzaldehyde in a Friedlander condensation 
with 2-fluorophenylacetontrile (see Zhang, W., et al. ACS
Chem Biol 8, 796-803 (2013)), and other heterocyclic fami­
lies is described in the synthesis section below. The con­
densation of 2-amino-4-(N,N-dimethylamino )benzaldehyde 
with 2-(2-fluorophenyl)acetyl chloride secured 7-(dimethyl­
amino)-3-(2-fluorophenyl)quinolin-2(1H)-one, and treat­
ment with Lawesson's reagent (see Goswami, A., et al. 
Cancer Res 68, 6190-6198 (2008)) provided 7-(dimethyl­
amino)-3-(2-fluorophenyl)quinoline-2(1H)-thione. S-alky­
lation of this intermediate with ( + )-biotinyl-iodoacetamidyl-
3,6-dioxaoctanediamine led to biotinylated Arylquin 9 (see 
the synthesis section below). Solvents were used from 
US 9,873,670 B2 
23 
commercial vendors without further purification unless oth­
erwise noted. Nuclear magnetic resonance spectra were 
determined on a Varian instrument (1 H, 400 MHz; 13C, 100
Mz). High resolution electrospray ionization (ESI) mass 
spectra were recorded on a LTQ-Orbitrap Velos mass spec- 5 
trometer (Thermo Fisher Scientific, Waltham, Mass., USA). 
The FT resolution was set at 100,000 (at 400 m/z). Samples 
were introduced through direct infusion using a syringe 
pump with a flow rate of 5 µUmin. MALDI mass spectra 
were obtained on a Bruker Utraflexstreme time-of-flight 10 
mass spectrometer (Billerica, Mass.), using DHB (2,5-dihy­
droxybenzoic acid) matrix. Purity of compounds was estab­
lished by combustion analyses by Atlantic Microlabs, Inc., 
Norcross, Ga. Compounds were chromatographed on pre­
parative layer Merck silica gel F254 unless otherwise indi- 15 
cat ed. 
Cells and plasmids: Human lung cancer cells H1299, 
HOP92, A549, H460, mouse lung cancer cells LLCl, human 
prostate cancer cells LNCaP, DU145, PC-3, and primary 
human lung fibroblast cells HEL and epithelial cells HBEC 20 
and BEAS-2B were from ATCC, MD; normal human pros­
tate epithelial cells PrE and human prostate stromal cells PrS 
were from Lonza Inc., Allendale, N.J. KP7B cells were from 
Tyler Jacks, MIT, MA. PC-3 derivatives PC-3 MM2 were 
from Sue-Hwa Lin, M.D. Anderson Cancer Center, Houston, 25 
Tex. Par-4+/+ and Par-4_1_ MEFs were derived from wild
type and Par-4-null C57BL/6 mice generated by Taconic. 
See Eckes, B., et al. J Cell Sci 113, 2455-2462 (2000). 
Vimentin-null (Vim-1-) and wild type MEFs, as well as 
vimentin-expressing (Vim+) and vimentin-deficient (Vim-) 30 
SW13 cells were from Anthony Brown (Ohio State Univer­
sity). 
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M. J Cell Phys 227, 3715-3721 (2012) and Shrestha-Bhat­
tarai, T., Hebbar, N. & Rangnekar, V. M. Cancer Cell 24, 3-5
(2013). A total of three independent experiments were
performed; and approximately 500 cells were scored in each 
experiment for apoptosis under a fluorescent microscope.
Cell surface GRP78 expression on the cancer cell surface
was quantified by FACS analysis in the Flow Cytometry
Shared Resource Facility, Markey Cancer Center as previ­
ously described. See Hebbar, N., Wang, C. & Rangnekar, V.
M. J Cell Phys 227, 3715-3721 (2012).
Animal experiments: C57BL/6 mice were injected via the
intraperitoneal route with Arylquin 1 (10 mg/kg body 
weight) or com oil vehicle, and whole-blood samples were 
collected 24 h later. Serum was separated from the blood 
samples, heated at 56° C. to inactivate complement. Aliquots 
of the mouse serum samples were added to the growth 
medium (final 20% mouse serum) of normal and cancer cells 
in culture and tested for induction of ex vivo apoptosis in 
cancer cells. All animal procedures were performed with 
University of Kentucky IACUC approval. 
Computational modeling: Molecular modeling of vimen­
tin binding with Arylquin 1 and the analogs was performed 
by using the previously reported computational protocol. Ee 
Hamza, A. et al., J Chem Inform Model 54, 1166-1173 
(2014) and Hamza, A. & Zhan, C.-G. J Phys Chem B 113, 
2896-2908 (2009). Briefly, each ligand was docked into the 
binding cavity and the resulting poses were refined by 
molecular dynamics (MD)-simulations. The most favorable 
binding mode (with the lowest binding free energy), which 
was identified in the docking procedure, was subjected to an 
MD simulation for 1 ns at 298 K and used in binding free 
energy calculations. 
Statistical analysis: All experiments were performed in 
triplicate to verify the reproducibility of the findings. The 
results show a mean of at least 3 experiments±Standard 
Deviation (s.d.). Statistical analyses were carried out with 
Statistical Analysis System software (SAS Institute, Cary, 
N.C.) and P values were calculated using the Student t test.
The effect of interaction between two different treatments
Antibodies and siRNA duplexes: Par-4 (R334), CollAl 
(H-197), Vimentin (H-84) for Western blot; Vimentin 
(RV202) for ICC and immunoprecipitation; GRP78 (N20), 35 
CollAl (H-197), p53 (D0-1) and pan-cytokeratin (Cl) 
antibodies were from Santa Cruz Biotechnology, Inc. Active 
caspase 3 antibody (Asp 17 5) ( 5A1E) and p53 antibody 
(1C12) were from Cell Signaling. The �-actin antibody was 
from Sigma Chemical Corp. 40 was analyzed using a two-way ANOVA model with data
normality and equality of variance assumptions.Pull down experiments: To identify the target protein for 
compound Arylquin 1, pull-down experiments were per­
formed as described previously. See Bargagna-Mohan, P., et 
al. J Biol Chem 285, 7657-7669 (2010). MEFs or HEL cells 
(grown to confluence in 15 cm plates) were lysed in 50 ml 45 
lysis buffer (40 mM Hepes, pH 7.8; 140 mM NaCl; 10 mM 
NaF; 10% Glycerol, 1 mM EDTA; 1 % Triton 100), and the 
lysates were pre-cleared at 4 ° C. for 1 h with 100 µL 
streptavidin beads (Novagen, Strep-Tactin Superflow Aga­
rose). Binding reactions were performed by incubating the 50 
pre-cleared cell lysates with 50 µL beads±25 µg of bioti­
nylated Arylquin 1 at 4° C. for 2 h. The beads were then 
washed four times with buffer (40 mM Hepes, pH 7.8; 140 
mM NaCl; 10 mM NaF; 10% Glycerol, 1 mM EDTA), and 
bound protein was eluted with 50 µL of 2.5 mM Biotin/PBS. 55 
Eluted proteins were resolved by SDS-PAGE and Coo­
massie blue staining. 
Co-Immunoprecipitation and Western blot analysis: Pro­
tein extracted from cell lysates was filtered, pre-cleared with 
25 µL (bed volume) of protein G-Sepharose beads and 60 
immunoprecipitated with 1 µg of respective antibodies. The 
eluted proteins were resolved by SDS-PAGE, and subjected 
to Western blot analysis as described. 
Apoptosis assays: Apoptotic nuclei were identified by 
immunocytochemical (ICC) analysis for active caspase-3, 65 
and nuclei were revealed by 4, 6-diamidino-2-phenylindole 
(DAPI) staining. See Hebbar, N., Wang, C. & Rangnekar, V. 
Synthesis of Compounds
FIG. 1 illustrates a general scheme for the synthesis of 
arylquins and depiction of Arylquin 1. Reagents: a, arylac­
etonitrile, tert-BuOK, DMF, 90° C., 3-4 h; b, 2(2'-fluoro­
phenyl)acetyl chloride, Et3N, reflux 2 h and then K2C03 , 
DMF, 90° C., 4 h; c, 2,4-bis( 4-methoxyphenyl)-2,4-dithi­
oxo-1,3,2,4-dithiadiphosphetane (Lawesson' s reagent), 
dioxane, reflux 5 h; d, ( + )-biotinyl-iodoacetamidyl-3,6-di­
oxaoctanediamine, K2C03, DMF, 12 h; e, POC13, reflux, 3 
h; f, Zn, CH3C02H, 75
° C., 1 h. 
General Procedure for the Synthesis of Arylquins. To a 
solution of 2.38 mmol (1.3 equiv) of the appropriate benzyl 
cyanide in 3 mL of anhydrous DMF at 0° C. was added 2.38 
mmol (1.3 equiv) of potassium tert-butoxide. The mixture 
was stirred for 15 min, and 1.83 mmol of appropriate 
2-aminobenzaldehyde dissolved in 1 mL of anhydrous DMF
was added dropwise at 0° C. The mixture was warmed to 25° 
C. and stirred for 3-4 h at 90° C. After cooling the mixture
was quenched by pouring into water to afford a precipitate
that was collected and purified by recrystallization and/or
chromatography as noted for individual compounds
described below.
3-(2-Fluorophenyl)-N7,N7 -dimethylquinoline-2, 7-di­
amine (Arylquin-1). Purified by recrystallization from etha­
nol: Yield 83%, mp 159-160° C. 1H NMR (DMSO-d6): Ii 
7.63 (s, lH), 7.50-7.41 (m, 3H), 7.33-7.28 (m, 2H), 6.86 (dd, 
US 9,873,670 B2 
25 26 
lH, 11=8.8 Hz, 12=2.8 Hz), 6.61 (d, lH, 1=2.8 Hz), 5.67 (s, Lawesson's reagent 16 in anhydrous 1,4-dioxane (10 mL) 
2H, NH2), 3.00 (s, 6H). 13C NMR (DMSO-d6): ll 160.09 (d, was stirred at reflux for 5 h. After cooling, a precipitate was 
1=242.6 Hz), 156.25, 151.88, 149.72, 137.78, 132.37 (d, collected, washed with 10% aqueous NaOH solution (5 mL) 
1=3.l Hz), 130.26 (d, 1=7.6 Hz), 128.58, 125.92 (d, 1=16.0 and water and dried in vacuum. The product was purified by 
Hz), 125.27 (d, 1=3.8 Hz), 116.47 (d, 1=22.1 Hz), 115.63, 5 recrystallization from acetonitrile to provide 350 mg (66%) 
114.33, 111.55, 104.16, 40.51 (two C). HRMS (ESI) calcd of 7-(dimethylamino)-3-(2-fluorophenyl)quinoline-2(1H)-
for C
17
H
17
FN
3 
[MH+]: 282.14010. Found: 282.14056. thione (Arylquin 5) as a pale yellow solid: mp 251-253° C. 
Anal. Calcd for C
17
H
16FN3 : C, 72.58; H, 5.73. Found: C, 
1H NMR (DMSO-d6): ll 13.24 (s, lH), 7.75 (s, lH), 7.58 (d, 
72.52; H, 5.79. lH, 1=9.2 Hz), 7.41-7.37 (m, 2H), 7.23-7.18 (m, 2H), 6.91 
3-(3-Fluorophenyl)-N7,N7-dimethylquinoline-2,7-di- 10 (dd, lH, 11=8.8 Hz, 12=1.8 Hz), 6.82 (d, lH, 1=1.8 Hz), 3.04 
amine (Arylquin 2) Purified by recrystallization from etha- (s, 6H). 13C NMR (DMSO-d6): ll 179.45, 159.51 (d, 1=242.9 
no!: Yield 84%, mp 147-148° C. 1H NMR (DMSO-d6): Ii Hz), 152.16, 141.29, 135.82, 132.20 (d, 1=3.2 Hz), 129.87, 
7.68 (s, lH), 7.53-7.48 (m, 2H), 7.34-7.30 (m, 2H), 7.23- 129.29 (d, 1=8.4 Hz), 128.81, 127.89 (d, 1=15.2 Hz), 123.75 
7.18 (m, lH), 6.86 (dd, lH, 11=8.8 Hz, 12=2.4 Hz), 6.61 (d, (d, 1=3.1 Hz), 115.16 (d, 1=22.0 Hz), 113.76, 111.61, 94.50, 
lH, 1=2.8 Hz), 5.69 (s, 2H, NH2), 3.00 (s, 6H). 13C NMR 15 39.77 (two C). HRMS (ESI) calcd for C
17
H
16FN2S [MH+]: 
(DMSO-d6): Ii 162.78 (d, 1=242.9 Hz), 155.85, 151.81, 299.10127. Found: 299.10176. Anal. Calcd for 
149.48, 141.22 (d, 1=7.6 Hz), 137.03, 131.18 (d, 1=8.4 Hz), C17H15FN2S: C, 68.43; H, 5.07. Found: C, 68.23; H, 5.18. 
128.69, 125.27 (d, 1=2.3 Hz), 119.17 (d, 1=2.3 Hz), 116.07, 3-(2-Fluorophenyl)-N,N-dimethylquinolin-7-amine 
115.93 (d, 1=21.3 Hz), 114.45 (d, 1=20.5 Hz), 111.63, (Arylquin 6) A mixture of 500 mg (1.77 mmol, 1 equiv) of 
104.07, 40.48 (two C). HRMS (ESI) calcd for C
17
H
17
FN
3 
20 7-(dimethylamino)-3-(2-fluorophenyl)quinolin-2(1H)-one 
[MH+]: 282.14010. Found: 282.14095. Anal. Calcd for (Arylquin 4) and 5 mL of phosphoryl chloride (POCl3) was 
C
17
H
1 6FN3 : C, 72.58; H, 5.73. Found: C, 72.54; H, 5.64. refluxed for 3 h. The mixture was poured on to ice and 
3-(4-Fluorophenyl)-N,N-dimethylquinoline-2,7-damine neutralized with 10% aqueous sodium carbonate solution at 
(Arylquin 3) Purified by recrystallization from acetonitrile: 0° C. A precipitate was collected by filtration, dried in vacuo 
Yield 91 %, mp 155-156° C. lH NMR (DMSO-d6): Ii 7.62 25 and purified by chromatography using 1:5 ethylacetate-
(s, lH), 7.53-7.48 (m, 3H), 7.31-7.27 (m, 2H), 6.85 (dd, lH, hexane (Rf=0.25) to afford 415 mg (78%) of 2-chloro-3-(2-
11=9.2 Hz, 12=2.8 Hz), 6.61 (d, lH, 1=2.4 Hz), 5.74 (s, 2H, fluorophenyl)-N,N-dimethylquinolin-7-amine as a pale yel-
NH2), 2.99 (s, 6H). 13C NMR (DMSO-d6): Ii 161.91 (d, low solid: mp 170-172° C. 1H NMR (DMSO-d6): ll 8.20 (s, 
1=242.l Hz), 156.13, 151.68, 149.34, 136.78, 135.11, lH), 7.83 (d, lH, 1=9.2 Hz), 7.54-7.46 (m, 2H), 7.36-7.29 
131.22 (d, 1=8.3 Hz, two C), 128.55, 119.53, 116.16, 116.08 30 (m, 3H), 6.95 (d, lH, 1=2.4 Hz), 3.09 (s, 6H). 13C NMR 
(d, 1=21.2 Hz, two C), 111.56, 104.16, 40.51 (two C). (DMSO-d6): Ii 159.36 (d, 1=243.6 Hz), 151.97, 148.83, 
HRMS (ESI) calcd for C17H17FN3 [MH+]: 282.14010. 148.76, 139.50, 132.05 (d, 1=3.0 Hz), 130.50 (d, 1=8.4 Hz), 
Found: 282.14085. Anal. Calcd for C
17
H
16
FN
3
: C, 72.58; H, 128.59, 125.54 (d, 1=16.0 Hz), 125.51 (d, 1=3.8 Hz), 122.92, 
5.73. Found: C, 72.31; H, 5.58. 118.79, 116.87, 115.52 (d, 1=21.2 Hz), 104.18, 39.86 (two 
7-(Dimethylamino)-3-(2-fluorophenyl)quinolin-2(1H)- 35 C). HRMS (ESI) calcd for C
17
H
14
CIFN
2 
[MH+]: 
one (Arylquin 4) To a mixture of 1.00 g (6.09 mmol) of 301.09023. Found: 301.08961. Anal. Calcd for 
2-amino-4-(dimethylamino)benzaldehyde 15 and 0.68 g Cl 7H14CIFN2: C, 67.89; H, 4.69. Found: C, 67.76; H, 4.52. 
(6.70 mmol, 1.1 equiv) of triethylamine in dichloromethane To a solution of 200 mg (0.66 mmol) of 2-chloro-3-(2-
(10 mL), we added 1.05 g (6.09 mmol, 1 equiv) of 2-(2- fluorophenyl)-N,N-dimethylquinolin-7-amine in 9 mL of 
fluorophenyl)acetyl chloride dropwise over a 15 min period. 40 glacial acetic acid and 0.7 mL of water at 75° C. was added 
The mixture was stirred at reflux for 2 h. After cooling to the 174 mg (2.66 mmol, 4 equiv) of zinc powder. After 1 h, the 
room temperature, the mixture was washed with 30 mL of mixture was quenched by addition of 40% aqueous sodium 
water, and the organic layer was separated, dried over hydroxide solution to a pH of 9-10. The solution was 
anhydrous MgS0
4 
and concentrated under reduced pressure. extracted with dichloromethane and the organic layer was 
The crude residue, obtained after concentration, was dis- 45 washed with water, dried over anhydrous MgS0
4 
and con-
solved in DMF (10 mL) followed by addition of 1.01 g (7.31 centrated under reduced pressure. The product was purified 
mmol, 1.2 equiv) of K
2
C0
3
. The resulting mixture was by chromatography using 1:2 ethylacetate-hexane to afford 
stirred at 90° C. for 4 h, poured into water and a precipitate 98 mg (55%) of 3-(2-fluorophenyl)-N,N-dimethylquinolin-
was collected by filtration and dried in vacuum. The product 7-amine (Arylquin 6) as a pale yellow solid: mp 142-144° C. 
was purified by recrystallization from acetonitrile to provide 50 lH NMR (DMSO-d6): Ii 8.86 (s, lH), 8.30 (s, lH), 7.84 (d, 
1.38 g (80%) of 7-(dimethylamino)-3-(2-fluorophenyl)qui- lH, 1=8.8 Hz), 7.70-7.60 (m, lH), 7.48-7.43 (m, lH), 
nolin-2(1H)-one (Arylquin 4) as a pale yellow solid: mp 7.39-7.32 (m, 3H), 7.02 (d, lH, 1=2.4 Hz), 3.09 (s, 6H). 13C 
247-248° C. 1H NMR (DMSO-d6): ll 11.52 (s, lH), 7.79 (s, NMR (DMSO-d6): Ii 159.33 (d, 1=244.3 Hz), 151.28, 
lH), 7.51-7.47 (m, 2H), 7.40-7.35 (m, lH), 7.25-7.20 (m, 150.24 (d, 1=3.8 Hz), 148.80, 134.71 (d, 1=3.0 Hz), 130.73 
2H), 6.69 (dd, lH, 11=8.8 Hz, 12=2.4 Hz), 6.48 (d, lH, 1=2.4 55 (d, 1=3.0 Hz), 129.61 (d, 1=8.4 Hz), 128.90, 125.75 (d, 
Hz), 3.00 (s, 6H). 13C NMR (DMSO-d6): ll 160.88, 159.75 1=13.6 Hz), 125.16 (d, 1=3.0 Hz), 123.78, 119.68, 116.78, 
(d, 1=244.3 Hz), 151.75, 140.74, 139.69 (d, l=l.5 Hz), 116.19 (d, 1=22.0 Hz), 105.53, 39.99 (two C). HRMS (ESI) 
131.89 (d, 1=3.8 Hz), 129.18 (d, 1=7.5 Hz), 128.97, 125.03 calcd for C17H15FN2 [MH+]: 267.12920. Found: 
(d, 1=15.2 Hz), 123.89 (d, 1=3.0 Hz), 121.09, 115.32 (d, 267.12839. Anal. Calcd for C
17
H
15FN2: C, 76.67; H, 5.68. 
1=22.0 Hz), 109.97, 108.65, 94.74, 39.76 (two C). HRMS 60 Found: C, 76.53; H, 5.52. 
(ESI) calcd for C
17
H
1 6
FN
2
0 [MH+]: 283.12412. Found: N7,N7-Dimethyl-3-phenylquinoline-2,7-diamine 
283.12473. Anal. Calcd for C
17
H
15 FN20: C, 72.32; H, 5.36. (Arylquin 7) Purified by chromatography on silica gel using 
Found: C, 72.19; H, 5.41. 1:10 methanol-dichloromethane (Rf=0.48): Yield 83%, mp 
7-(Dimethylamino )-3-(2-fluorophenyl)quinoline-2(1H)- 123-125° C. 1H NMR (DMSO-d6): ll 7.64 (s, lH), 7.52-7.46 
thione (Arylquin 5) A mixture of 500 mg (1.77 mmol, 1 65 (m, SH), 7.41-7.36 (m, lH), 6.86 (dd, lH, 11=8.6 Hz, 12=2.6 
equiv) of 7-(dimethylamino)-3-(2-fluorophenyl)quinolin-2 Hz), 6.62 (d, lH, 1=2.4 Hz), 3.00 (s, 6H). 13C NMR 
(lH)-one (Arylquin 4) and 716 mg (1.77 mmol, 1 equiv) of (DMSO-d6): Ii 155.55, 151.25, 148.68, 138.28, 136.34, 
US 9,873,670 B2 
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taining heterocyclic rings imbedded within their structures. 
We screened representative members of each of these het­
erocyclic families on a compound-by-compound basis for 
the secretion of Par-4 protein from normal mouse fibroblasts 
128.88 (two C), 128.66 (two C), 128.15, 127.29, 120.05, 
115.77, 111.15, 103.63, 40.07 (two C). HRMS (ESI) calcd 
for C17H18N3 [MH+]: 264.14952. Found: 264.15024. 
Anal. Calcd for C17H17N3: C, 77.54; H, 6.51. Found: C, 
77.27; H, 6.43. 5 under conditions that were not toxic to the cells. Initial 
3-(2-Fluorophenyl)quinolin-2-amine (Arylquin 8) Puri­
fied by chromatography on silica gel using 1: 10 methanol­
dichloromethane (Rf=0.55): Yield 79%, mp 152-153
° C. 1H
NMR (DMSO-d6): Ii 7.87 (s, lH), 7.70 (d, lH, 1=8.0 Hz), 
7.55-7.44 (m, 4H), 7.37-7.32 (m, 2H), 7.22-7.18 (m, lH), 10 
6.03 (s, 2H, NH2). 13C NMR (DMSO-d6): Ii 159.56 (d, 
1=243.6 Hz), 155.85, 147.59, 137.86, 131.77 (d, 1=3.3 Hz), 
130.36 (d, 1=8.0 Hz), 129.52, 127.65, 124.95, 124.90, 
124.77 (d, 1=16.1 Hz), 122.80, 121.59, 118.76, 116.11 (d, 
1=22.2 Hz). HRMS (ESI) calcd for C15H12FN2 [MH+]: 15 
239.09790. Found: 239.09831. Anal. Calcd for C15H11FN2: 
C, 75.62; H, 4.65. Found: C, 72.39; H, 4.71. 
N-(2-(2-(2-(2-(7-( dimethylamino )-3-(2-fluorophenyl) 
quinolin-2-ylthio )acetamido )ethoxy)ethoxy )ethyl)-5-(2-
oxohexahydro-l H-thieno[3 ,4-d]imidazol-4-y l)pentanamide 20 
(Biotinylated Arylquin 9). To a solution of 28 mg (0.092 
mmol) of 7-( dimethylamino )-3-(2-fluorophenyl)quinoline-2 
(lH)-thione in 1 mL ofDMF was added 15 mg (0.11 mmol, 
1.2 equiv) of K2C03 and 50 mg (0.092 mmol) of ( + )­
biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine. The mix- 25 
ture was stirred for 12 h at 25° C., poured into water,
extracted with dichloromethane, dried over anhydrous 
MgS04 and concentrated under reduced pressure. The prod­
uct was purified by chromatography 1:10 methanol-dichlo­
romethane (Rf=0.25) to afford 29 mg (44%) ofbiotinylated 30 
Arylquin 9 as a pale yellow solid: 1H NMR (DMSO-d6): Ii
8.03 (t, lH, 1=4.8 Hz), 7.70 (s, lH), 7.59 (d, lH, 1=8.8 Hz),
7.44-7.35 (m, 2H), 7.23-7.14 (m, 2H), 7.08 (dd, lH, 11=8.8
Hz, 12=2.8 Hz), 7.00 (d, lH, 1=2.4 Hz), 6.42 (t, lH, 1=4.8 
Hz), 6.07 (br s, lH), 5.07 (br s, lH), 4.43-4.40 (m, lH), 35 
4.25-4.22 (m, lH), 3.92 (s, 2H), 3.48-3.46 (m, 2H), 3.43-
3.39 (m, 2H), 3.32-3.28 (m, 6H), 3.21-3.19 (m, 2H), 3.12 (s, 
6H), 3.09-3.05 (m, lH), 2.84 (dd, lH, 11=12.8 Hz, 12=4.8 
Hz), 2.66 (d, lH, 1=12.8 Hz), 2.14 (t, 2H, 1=8.0 Hz), 
1.68-1.56 (m, 4H), 1.41-1.36 (m, 2H). 13C NMR (DMSO- 40 
d6): Ii 173.32, 170.59, 163.70, 160.28, 157.28, 152.12, 
149.30, 136.68, 132.41 (d, 1=2.1 Hz), 130.71 (d, 1=8.0 Hz),
128.67, 125.27 (d, 1=16.1 Hz), 124.45 (d, 1=3.4 Hz), 123.95, 
118.38, 116.14 (d, 1=22.2 Hz), 115.46, 107.65, 105.43, 
70.26, 70.15, 70.00, 69.92, 61.94, 60.29, 55.59, 40.72, 45 
39.75, 39.23, 36.08, 33.82, 29.92, 28.31, 28.26, 27.72. 
MALDI-TOF MS calcd for C35H46FN605S2 [MH+]: 
713.2955. Found: 713.2936. 
Testing of Arylquinolines for Promoting Secretion of Par-4 
expectations were that these heterocycles would serve as 
Nutlin-3a surrogates and inhibit MDM2, but studies 
reported herein established a completely different mecha-
nism of action, reflecting that the structural dissimilarities 
between these heterocycles and Nutlin-3a outweighed the 
similarities that led to their initial selection for screening. 
Within this library of compounds, the fluorinated 
3-arylquinolines proved particularly promising in promoting
Par-4 secretion. Structure-activity studies defined that
3-arylquinolines, such as Arylquin 1, was most active as the
leading member of a new class of "small-molecule" Par-4
secretagogues. Arylquin 1 produced a dose-dependent secre­
tion in MEF cells. Arylquin 1 also induced robust secretion
of Par-4 in normal/immortalized human cells, but failed to
induce the secretion of Par-4 in a panel oflung tumor cells.
By contrast, prostate cancer cells showed induction of Par-4
secretion with Arylquin 1 relative to vehicle control. Con­
sistent with previous studies, Brefeldin A, which blocked
anterograde endoplasmic reticulum-Golgi traffic, inhibited
basal as well as Arylquin I-inducible Par-4 secretion. See
Hebbar, N., Wang, C. & Rangnekar, V. M. J Cell Phys 227,
3715-3721 (2012). These findings indicated that Arylquin 1
regulated Par-4 secretion via the classical secretory pathway. 
To identify the molecular target responsible for the 
observed Par-4 secretory activity, we synthesized a bioti­
nylated Arylquin 9. Biotinylated Arylquin 9 was confirmed 
experimentally to retain Par-4 secretory properties and was 
then used in pull-down experiments for potential protein 
targets in mouse fibroblasts (MEFs) and human fibroblasts 
(HEL). 
We identified vimentin, a cytoskeletal intermediate fila­
ment protein, as its principal target. The binding of Par-4 to 
vimentin was experimentally confirmed by co-immunopre­
cipitation experiments: the Par-4 antibody co-immunopre­
cipitated endogenous vimentin, and the vimentin antibody 
co-immunoprecipitated endogenous Par-4. Immunocyto-
chemical analysis confirmed that Par-4 co-localized with 
vimentin. On the other hand, cells treated with Arylquin 1 
showed neither Par-4 co-immunoprecipitation nor co-local­
ization with vimentin, indicating that Arylquin 1 displaced 
Par-4 from vimentin. This action of Arylquin 1 was not 
associated with inhibition of vimentin expression, suggest­
ing that Arylquin 1 may cause conformational changes in 
vimentin to inhibit its ability to bind and sequester Par-4 or 
To identify Par-4 secretagogues, we synthesized and 
screened 3-arylquinolines as well as related quinolones and 
quinothiolones for the secretion of Par-4 protein from nor­
mal fibroblasts under conditions that are not toxic to the 
cells. 
50 compete for a hydrophobic binding region on vimentin 
crucial for Par-4 binding. The differential regulation of Par-4 
secretion in normal and various cancer cells by Arylquin 1 
may reflect distinct posttranslational modification patterns 
of Par-4 and/or vimentin; studies are underway to address 
55 the underlying mechanism. Nutlin-3a, originally developed as an MDM2 inhibitor, 
stimulated Par-4 secretion at micromolar levels in mouse 
embryonic fibroblast (MEF) cells. The presence of halogen 
substituents on an aromatic ring, two aromatic rings sepa­
rated by a two-atom spacer (i.e., 1,2-diphenylethane subunit) 
and a nitrogen-containing heterocycle (i.e., an imidazole 
subunit) in Nutlin-3a enabled us to screen an in-house 
library that possessed similar features, namely halogenated 
aromatic rings separated by two-atom spacers (i.e., 1,2-
diphenylethene or stilbene subunits) and nitrogen-contain­
ing heterocycles. Specifically, we focused on halogenated 65 
3-arylquinolines, 3-arylquinolones, and 3-arylthioquinolo­
nes, which possessed stilbene subunits and nitrogen-con-
Computer modeling using molecular dynamics simula­
tions led to a minimum-energy structure in which Arylquin 
1 binds tetrameric vimentin in a hydrophobic pocket that lies 
between a pair of head-to-tail a-helical dimers. The spatial 
60 arrangement of functional groups within Arylquin 1 was 
ideally suited to stabilize binding to vimentin. Additional 
modeling revealed that Arylquin 1 and its analogs examined 
bind vimentin in the same orientation but with different 
binding energies. The relative values of the calculated 
binding energies are qualitatively consistent with experi­
mental trends: Arylquin 1, Arylquin 6 and Arylquin 8 with 
the largest binding energies promoted the highest levels of 
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Par-4 secretion. The fluorine group in Arylquin 1 was 
indispensable for activity, and the removal of the fluorine 
was accompanied by reduced binding and concomitant loss 
of Par-4 secretory. 
30 
Because targeting vimentin may induce apoptosis, we 
tested normal cells and diverse cancer cells for apoptosis by 
Arylquin 1. Arylquin 1 induced the dose-dependent apop­
tosis in cancer cells but not in normal cells (FIG. 2). 
Importantly, 500 nM amounts of Arylquin 1, which triggered 
secretion of Par-4 from normal cells but not lung cancer 
cells, did not directly induce apoptosis in normal or cancer 
cells. By contrast, 500 nM amounts of Arylquin 1 induced 
apoptosis of PC-3 cells and its derivative PC-3MM2, which 
are sensitive to apoptosis by Par-4, but not in LNCaP or 
DU145 cells, which are resistant to apoptosis by Par-4. 
which implicated Par-4 secreted from normal cells in the 
apoptotic death of cancer cells, were corroborated by the 
observation that Arylquin 1 treatment of cancer cells co­
cultured with Par-4-null normal cells failed to induce apop­
tosis of the cancer cells. Thus, Arylquin 1 induced paracrine 
apoptosis in cancer cells via Par-4 secreted by normal cells. 
Because Par-4 produced apoptosis in diverse tumors and 
because there were no previously reported compounds that 
acted at nanomolar concentrations to produce the levels of 
10 Par-4 secretion discovered in this study, these findings have 
potential, translational significance. 
While the claimed invention has been described in detail 
and with reference to specific embodiments thereof, it will 
15 be apparent to one of ordinary skill in the art that various 
We next tested co-cultures of normal cells with cancer 
cells for the apoptotic effect of Arylquin 1 at 500 nM, as this 
low concentration induced the secretion of Par-4 from 
normal cells yet did not induce apoptosis in normal or cancer 
cells. Arylquin 1 treatment of the co-cultures containing 
Par-4+/+ MEFs and cancer cells resulted in apoptosis of the 
cancer cells, relative to vehicle-treatment (FIG. 3 top). Only 
the cancer cells, but not normal HEL cells, underwent 
apoptosis in such co-culture experiments. By contrast, 
Arylquin 1 treatment of the co-cultures containing Par-4_1_ 
MEFs and cancer cells did not induce apoptosis. Paracrine 
apoptosis induced in the cancer cells by Par-4, which was 
secreted from Par-4+1+ MEFs but not Par-4_1_ MEFs in 
response to Arylquin 1 treatment, was mediated via cell 
surface GRP78 (FIG. 4). Moreover, vimentin-deficient cells 30 
showed robust increase in secretion of pro-apoptotic Par-4 
activity in the CM relative to counterpart wild type cells, and 
Arylquin 1 did not further induce Par-4 secretion in these 
cells (FIG. 5). Based on these findings, we infer that: (a) 
vimentin sequestered Par-4 and prevented its secretion, and 35 
(b) Arylquin 1 bound to vimentin and thereby altered the
vimentin-Par-4 association to facilitate Par-4 secretion.
changes and modifications can be made to the claimed 
invention without departing from the spirit and scope 
thereof. Thus, for example, those skilled in the art will 
20 recognize, or be able to ascertain, using no more than routine 
experimentation, numerous equivalents to the specific sub­
stances and procedures described herein. Such equivalents 
are considered to be within the scope of this invention, and 
25 are covered by the following claims. 
To determine the physiological significance of these find­
ings, we injected immunocompetent mice withArylquin 1 or 
vehicle and examined their serum for circulating levels of 40 
Par-4. Arylquin 1 produced 5-fold higher Par-4 secretion 
relative to vehicle control in serum (FIG. 3 bottom). Serum 
from the Arylquin 1 treated mice, but not vehicle-treated 
mice, produced significantly higher (P<0.001) ex vivo apop­
tosis of cancer cell cultures (FIG. 3 bottom). The pro- 45 
apoptotic activity in the serum was neutralized by the Par-4 
antibody. These findings implied that systemic Par-4 levels 
were elevated in response to Arylquin 1 treatment and that 
these levels were effective in producing apoptosis of cancer 
cells. 50 
What is claimed is: 
1. A method for alleviating, ameliorating, or lessening the
severity of cancer in a subject in need thereof comprising 
administering to the subject an effective amount of the 
compound of formula (I): 
(I) 
or a pharmaceutically acceptable salt thereof; 
wherein n is 1, 2, 3, 4, 5, or 6, for each NR1 R2, R1 and R2 
are independently H, alkyl, alkoxy, aryl, heteroaryl; Ar 
is aryl or heteroaryl, which can be further substituted 
with halogen, amino, alkylamino, dialkylamino, aryl­
alkylamino, N-oxides of dialkylamino, trialkylammo-
nium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, 
cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, 
sulfonamide, CONR3R4, NR3CO(R4), NR3COO(R4), 
NR
3
CONR
4
R
5 
where R
3
, R
4
, R
5
, are independently, H, 
alkyl, aryl, heteroaryl or a fluorine; X represents halo-
gen; m is 1, 2, 3, 4, or 5, 
wherein the cancer is selected from prostate cancer or 
lung cancer. 
In summary, the present study identified a novel secret­
agogue, Arylquin 1, that produced a dose-dependent secre­
tion of Par-4 at nanomolar concentrations from both normal 
fibroblasts and epithelial cells. Vimentin was the primary 
target of Arylquin 1, as determined using a biotinylated 55 
analog of Arylquin 1. Vimentin represents a particularly 
important therapeutic target because of its elevation in 
diverse tumors and its causal role in EMT and metastasis 12 . 
Importantly, this chemical genetics approach led to the 
identification of vimentin as a novel binding partner of Par-4 
and indicated that Arylquin 1 exhibited its function by 
binding to vimentin and releasing vimentin-bound Par-4 for 
secretion. At low concentrations, Arylquin 1 by itself did not 
kill normal cells and most cancer cells, but instead, it caused 
robust secretion of Par-4 from normal cells and triggered 65 
apoptosis in cancer cells only when they were used in 
co-culture experiments with normal cells. These findings, 
2. The method according to claim 1, wherein n is 2 and
one NR1 R2 group is at the 2 position of the quinoline ring 
60 and the another NR
1 
R
2 
group is at the 7 position of the 
quinoline ring and the Ar-Xm group is at the 3 position of 
the quinoline ring. 
3. The method according to claim 2, wherein m is 1 or 2,
Ar is phenyl and X is selected from fluoro or chloro. 
4. The method according to claim 2, wherein Ar is
heteroaryl. 
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5. A compound according to formula (I):
32 
8. A biotinylated derivative of the compound according to 
claim 5. 
(I) 
9. A pharmaceutically acceptable composition comprising
a compound of claim 5 and a pharmaceutically acceptable 
5 additive. 
or a pharmaceutically acceptable salt thereof; 
wherein n is 1, 2, 3, 4, 5, or 6, for each NR
1 
R
2
, R
1 
and R
2 
are independently H, alkyl, alkoxy, aryl, heteroaryl; Ar 
10 
10. A method of alleviating, ameliorating, or lessening the
severity of cancer in a subject in need thereof comprising 
administering to the subject an effective amount of a phar­
maceutically acceptable composition of claim 9, 
wherein the cancer is selected from prostate or lung 
cancer. 
11. The method of claim 1, wherein n is 2; R
1 
and R
2 
are 
independently H, or alkyl; Ar is aryl substituted with alkoxy; 
and m is 1; and wherein one NR
1 
R
2 
group is at the 2 position 
of the quinoline ring and the another NR
1
R
2 
group is at the 
15 7 position of the quinoline ring and theAr-Xm group is a the 
3 position of the quinoline ring and X is selected from the 
fluoro or chorlo. 
is aryl or heteroaryl, which can be further substituted 
with halogen, amino, alkylamino, dialkylamino, aryl­
alkylamino, N-oxides of dialkylamino, trialkylammo­
nium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, 
cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, 
sulfonamide, CONR
3
R
4
, NR
3
CO(R
4
), NR
3
COO(R
4
), 
20 
NR
3
CONR
4
R
5 
where R
3
, R
4
, R
5
, are independently, H, 
alkyl, aryl, heteroaryl or a fluorine; X represents halo­
gen; m is 1, 2, 3, 4, or 5. 
12. The compound of claim 5, wherein n is 2; R
1 
and R
2 
are independently H, or alkyl; Ar is aryl substituted with 
alkoxy; and m is 1; and wherein one NR
1 
R
2 
group is at the 
2 position of the quinoline ring and the another NR
1 
R
2 
group 
6. The compound of claim 5, wherein n is 1 or 2; for each
25 
NR
1 
R
2
, R
1 
and R
2 
are independently H, or a lower alkyl; Ar 
is at the 7 position of the quinoline ring and theAr-Xm group 
is at the 3 position of the quinoline ring and X is selected 
from fluoro or chloro. 
13. The pharmaceutically acceptable composition of
claim 9, wherein n is 2; R
1 
and R
2 
are independently H, or 
alkyl; Ar is aryl substituted with alkoxy; and m is 1 ; and 
wherein one NR
1
R
2 
group is at the 2 position of the 
quinoline ring and the another NR
1 
R
2 
group is at the 7 
is phenyl; m is 1 or 2; and X is selected from fluoro or 
chloro. 
7. The compound of claim 5, wherein the compound is
3-(2-fluorophenyl)-N7 ,N7 -dimethylquinoline-2, 7-diamine; 
3-(3-fluorophenyl)-N7 ,N7 -dimethylquinoline-2, 7-diamine; 
3-( 4-fluoropheny l)-N7 ,N7 -dimethy lquinoline-2, 7 -diamine; 
3-(2-fluorophenyl)-N,N-dimethylquinolin-7-amine; 3-(2-
fluorophenyl)quinolin-2-amine. 
30 position of quinoline ring and the Ar-Xm group is at the 3 
position of quinoline ring and X is selected from fluoro or 
chloro. 
* * * * *
